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INFERENCE, POWER AND SAMPLE SIZE FOR ADAPTIVE TWO-STAGE
TREATMENT STRATEGIES
Wentao Feng, PhD
University of Pittsburgh, 2008
An adaptive treatment strategy (ATS) is defined as a sequence of treatments and interme-
diate responses. ATS’ arise when chronic diseases such as cancer and depression are treated
over time with various treatment alternatives depending on intermediate responses to ear-
lier treatments. For example, in two-stage adaptive treatment strategies, patients receive
one of the induction treatments followed by a maintenance therapy given that the patients
responded to the induction treatment they received. Clinical trials are often designed to
compare adaptive treatment strategies based on appropriate designs such as sequential ran-
domization designs. One of the main objectives of these trials is to compare two or more
treatment strategies in terms of largest patient benefit, such as prolonged survival.
Statistical inference from such trials needs to account for the sequential randomization
structure of the design. Recent literature suggests several methods of estimation. A com-
parative review of available inferential procedures for analyzing data from such trials is
presented. A sample size formula is introduced for comparing the survival probabilities un-
der two treatment strategies sharing the same initial treatment. The formula is based on
the large sample properties of inverse-probability-weighted estimator. Monte Carlo simula-
tion study shows strong evidence that the proposed sample size formula guarantees desired
power, regardless of the true distributions of survival times.
To test for a difference in the effects of different induction and maintenance treatment
combinations, a supremum weighted log-rank test is proposed. The test is applied to a
dataset from a two-stage randomized trial and the results are compared to those obtained
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using a standard weighted log-rank test. A sample-size formula is derived based on the
limiting distribution of the supremum weighted log-rank statistic. Simulation studies show
that the proposed test provides sample sizes which are close to those obtained by standard
weighted log-rank test under a proportional hazard alternative. However, the proposed test
is more powerful than the standard weighted log-rank test under non-proportional hazard
alternatives.
The public health significance of this work is to provide a practical guidance of sample
size determination and a test procedure in clinical trials that adopt two stage randomization
designs.
Keywords: Adaptive treatment strategy; Brownian motion; Counting process; Inverse-
probability-weighting; Potential outcomes; Proportional hazards; Supremum log-rank
statistic; Survival function; Two-stage randomization design.
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1.0 INTRODUCTION
1.1 ADAPTIVE TREATMENT STRATEGIES
An adaptive treatment strategy (also known as dynamic treatment regime) is an individually
tailored series of decision rules specifying how treatment option should vary over time. The
rule at each stage uses time-varying measurements of response, adherence, and other patient
characteristics up to that point to determine the next treatment type and/or dosage. The
decision rules comprising a treatment regime are made prior to the beginning of the course
of treatment. Dynamic treatment regimes are widely used in the treatment of chronic or
complex diseases such as cancer, AIDS, hepatitis and mental illness, where the presence of
heterogeneity in response, potential for relapse, variability of patients characteristics and
problems with adherence demands the adjustments of clinical decisions over time. The
objective in developing such multistage decision-making strategies is to improve patient
outcomes over time. The study of sequenced treatment alternatives to relieve depression
(STAR*D) by Rush et al. [1] is one such example where patients were treated according
to one of several available treatments (or different doses of same drug) for a fixed period of
time and then based on the intermediate response were switched to a different treatment.
The main objective of such trials is to compare different treatment strategies in search of
the best one.
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Figure 1.1: A typical two-stage randomization design: full circles, rectangles and arched
rectangles represent respectively the time of randomization, available treatment arms and
the intermediate outcome.
1.2 TWO-STAGE RANDOMIZATION DESIGNS
Randomized clinical trials comparing treatment strategies with randomization being done
upfront to all possible strategies require large number of patients, even when the number
of stages and the number of treatment choices at each stage are small. For instance, a
clinical trial comparing treatment strategies with three stages and two possible treatment
options at each stage requires randomization to 23 = 8 possible regimes. By considering the
natural course of treatment, one could randomize patients at the beginning of each stage
once they become eligible. For example, to compare treatment strategies for a dynamic
treatment regime with two stages and two treatment options at each stage, patients could
be randomized to one of two possible therapies and depending on the intermediate response,
could be randomized to further therapies at stage two. Such multistage randomization
designs are referred to as sequential multiple assignment randomization trial or SMART
[2]. A pictorial representation of a standard two-stage design is given in Figure 1.1. The
treatment options Bj and B
′
j , j = 1, 2 may be same or different depending on specific
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clinical trials. Unlike the situation described in Figure 1.1, where every patient receives
some therapy at each stage, there may be cases where therapy may be stopped after the
first stage if certain clinical conditions are not met. In the CALGB clinical trial described
below, the non-responding patients did not receive further treatment in the second stage.
For a two-stage design where therapy is stopped for patients not responding to the initial
treatment, the branches involving B′j , j = 1, 2 in Figure 1.1 will be missing. In such
cases one could assume that the non-responding patients will receive a common treatment.
Clinical trials employing two-stage randomization designs are commonly implemented in
biomedical research. We describe two such clinical trials that motivated the methodologies
in our research.
1.3 CALGB 8923 TRIAL
Cancer and Leukemia Group B (CALGB) conducted a two-stage clinical trial (Protocol 8923)
to investigate the combination of different induction and maintenance therapies. As reported
by Stone et al. [3], 388 AML (acute myelogenous leukemia) patients 60 years of age or older
participated in this double-blind, placebo controlled trial. Following standard chemotherapy,
in the first stage, 195 of these patients were randomly assigned to receive placebo and 193
receive granulocyte-macrophage colony-stimulating factor (GM-CSF). 79 in the GM-CSF
group and 90 in the placebo group achieved complete remission and consented to further
treatment. In the second stage, 37 GM-CSF and 45 placebo patients were randomly assigned
to receive intensification therapy I, and the rest 42 GM-CSF patients and 45 placebo patients
to intensification therapy II. The purpose of the trial was to examine the effects of infusions
of GM-CSF after initial chemotherapy for elderly patients with AML.
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1.4 E4494 CLINICAL TRIAL
The E4494 clinical trial conducted by the Eastern Cooperative Oncology Group (ECOG),
CALGB and the Southwest Oncology Group (SWOG) and reported by Winter et al. [4] is
another example of TSRD. This study was aimed to address the impact of the addition of
rituximab to standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)
therapy during induction with a second randomization to maintenance rituximab (MR) or
observation on early and late treatment failures in diffuse large B-cell lymphoma (DLBCL) in
elderly patients. Among the 632 previously untreated patients 60 years of age or older with
DLBCL, 318 were randomized to the induction treatment with addition of rituximab(R) to
CHOP, and 314 to standard CHOP. In the second stage, out of 415 responding patients, 207
were then randomized to MR and 208 to observation. After ineligibility exclusion, there were
267 R-CHOP and 279 CHOP patents in the induction stage, 174 MR and 178 observation
patients in maintenance stage. The goal of the study was to compare the risk of treatment
failure, time-to-treatment failure and overall survival among different treatment policies.
1.5 MOTIVATION AND PURPOSE
Traditional methods for analyzing data from two-stage trials separate the two stages, for
example, first estimate and compare the survival distributions between two induction treat-
ments for all patients in the study, ignoring the maintenance therapy, then for all responding
patents, estimate and compare their survival distributions between two maintenance thera-
pies conditioning on the response, regardless of the induction therapy they had received. The
outcome of interest in the second stage is usually taken as the length of time from receiving
the maintenance therapy to death or failure. Contrary to implementing intention-to-treat
analysis which will be addressed in the following chapters, such methods discard informa-
tion from the patients who could have potentially received the therapy and consequently
reduces the effective sample size and makes the analysis inefficient. More importantly, such
methods of analysis are limited to comparing different induction treatments or maintenance
4
treatments, without being able to address the question of finding the best combination of
induction and maintenance therapies.
For the cases where the outcome of the study is survival time, Lunceford et al. [5]
proposed a class of consistent, asymptotically normal estimators for the survival distribution
of treatment policies. Their framework allowed consistent estimation of survival distributions
under intent-to-treat treatment policies. However, these estimators were not efficient and
failed to use the auxiliary information collected in the form of covariates. Wahed and Tsiatis
[6] obtained the most efficient semi-parametric regular asymptotically linear estimators for
survival distribution and related quantities borrowing the idea of semi-parametric theory
from Robins et al. [7]. The estimators proposed incorporated auxiliary time independent
and time dependent covariates to gain efficiency. The cases of where the data may be right
censored, were incorporated in Wahed and Tsiatis [8]. Considering the impractical nature
of the most efficient estimator, they also proposed estimators that are easy to compute but
are more efficient than Lunceford et al. [5] estimators. Lokhnygina and Helterbrand [9]
employed Cox’s proportional hazard model to derive a consistent estimator and score test
for the log hazard ratio. Guo and Tsiatis [10] proposed a weighted risk set estimator (WRSE)
for the survival distribution with right censoring using the concepts of counting process and
risk sets described by Fleming and Harrington [11]. Recently, Guo [12] proposed a weighted
log-rank test for testing the equality of two survival curves under two different strategies
sharing the same maintenance therapy. However, as noted in Eng and Kosorok [13], this test
has low power for detecting time-varying relative hazards.
There have been quite a few innovative procedures, some of which were mentioned above,
to make inferences regarding adaptive treatment strategies based on the data collected from
sequentially randomized designs. However, few techniques are available with respect to the
design of such trials. For example, an important problem that has yet to be addressed is
the power analysis and sample size determination to compare two or more strategies, or to
detect a particular class of alternatives.
The notation and assumptions used throughout our research are introduced in chapter
2. The first part of this research provides an exhaustive and comparative review of ana-
lytical approaches available for the two-stage randomization designs with survival time as
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the primary outcome. Comparative conclusions are drawn based on the simulation stud-
ies. The results are presented in chapter 3. In the second part of the research, we present
a sample size formula to compare the point-wise survival probabilities for different treat-
ment strategies using Wald’s test. The formula is based on the large sample properties of
inverse-probability-weighted estimator. Simulation study provides strong evidence that the
proposed sample size formula guarantees desired power, regardless of the true distributions
of survival time. Results are presented in Chapter 4. In the final part of this thesis, for the
purpose of testing the equality of survival distributions of two adaptive treatment strategies,
a supremum weighed log-rank test is proposed, and a sample size formula is derived based
on the limiting distribution of the supremum weighted log-rank test statistic, as elaborated
in chapter 5. Simulation studies show that the proposed test provided sample sizes that
are close to those obtained by standard weighted log-rank test under a proportional hazard
alternative. Some remarks and potential future research are discussed in chapter 6.
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2.0 MODEL FRAMEWORK AND NOTATION
Let us consider a two-stage clinical trial similar to the CALGB 8923 Study , where the
induction treatment is A, with levels A1 and A2, and the maintenance treatment is B,
with levels B1 and B2. The objective is to compare the survival distributions for different
treatment policies AjBk, j, k = 1, 2, where AjBk stands for “treat with Aj followed by Bk if
the patient is eligible and consents to subsequent maintenance therapy.”
Let us assume that each patient i has an associated set of random variables, also referred
to as potential outcomes, {R∗1i, R∗2i, (1 − R∗1i)T ∗10i, (1 − R∗2i)T ∗20i, R∗1iTR∗1i , R∗2iTR∗2i , R∗1iT ∗11i,
R∗1iT
∗
12i, R
∗
2iT
∗
21i, R
∗
2iT
∗
22i, Vi}, where R∗ji is the eligible/consent status that patient i would
achieve were s/he assigned to one of the two policies AjBk, j, k = 1, 2, R
∗
ji = 1 if patient
i was eligible and would consent to subsequent maintenance treatment, Rji = 0 otherwise;
T ∗j0i is the survival time of patient i if s/he received induction treatment Aj, and was not
eligible or refused subsequent maintenance treatment, defined only when R∗ji = 0; T
R∗
ji is
the time from initial randomization to Aj to the time s/he received maintenance therapy,
defined only when R∗ji = 1; T
∗
jki is the survival time of patient i if s/he received induction
treatment Aj, was eligible and consented to receive maintenance treatment and received Bk;
Vi is a vector of auxiliary covariates including relevant baseline characteristics for patient i.
From the definition above, we can see that TR∗ji is defined only for those eligible and consent
patients, and all of the ten variables R∗1i, R
∗
2i, T
∗
10i, T
∗
20i, T
R∗
1i , T
R∗
2i , T
∗
11i, T
∗
12i, T
∗
21i and T
∗
22i
can not be observed for the same patient since a patient can receive only one of the two
induction treatments, can not be both responder and non-responder, and can only receive
one of the two maintenance treatments if s/he responds in the 1st stage. These variables,
for such reason, are referred to as counterfactuals [14, 15] or potential random variables.
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With the above notations, the survival time for patient i who received treatment policy
AjBk would be Tjki = (1−R∗ji)T ∗j0i+R∗jiT ∗jki. Due to the fact that some patients eligible for
maintenance therapy Bk may not consent to further treatment or may be randomized to the
maintenance therapy B3−k, k = 1, 2 , the inference on features of these distributions addresses
directly the ”intent-to-treat” question of interest. With the above conceptualization, the
primary goal is to estimate parameters and draw inference on the distribution of Tjk, j, k =
1, 2. Specifically, we consider the problem of estimating Sjk(t) = Pr(Tjk > t) = E{I(Tjk >
t)}, the survival probability beyond time t for treatment policy AjBk. In other cases, possible
parameters of interest can be the mean or median restricted survival time.
If there is no censoring, the observed data can be represented as a set of i.i.d ran-
dom vectors {Zi, Ri, RiTRi , (1 − Ri)T0i, Vi, RiXi, Ti}, i = 1, · · · , n, where Zi denotes the A
treatment randomization, i.e, Zi = 2 − j if the ith patient is assigned to treatment Aj,
j = 1, 2; Ri = ZiR
∗
1i + (1 − Zi)R∗2i is the observed eligible/consent status for patient i;
TRi = ZiT
R∗
1i + (1−Zi)TR∗2i ; T0i = ZiT ∗10i + (1−Zi)TR20i,; Vi is a vector of auxiliary covariates
as defined before; Xi denotes the B treatment assignment indicator, defined only if Ri = 1 ,
where Xi = 2− k if assigned to treatment Bk,k = 1, 2; and Ti is the observed survival time
for patient i. Following stable unit treatment value assumption [16], we assume that the
observed survival time for patient i is related to the potential outcomes through the relation
Ti = Zi {(1−R∗1i)T ∗10i +R∗1i(XiT ∗11i + (1−Xi)T ∗12i)}
+(1− Zi) {(1−R∗2i)T ∗20i +R∗2i(XiT ∗21i + (1−Xi)T ∗22i)} , (2.1)
that is, for a patient who receives induction treatment Aj, if s/he is observed to be a
non-responder, then his/her observed survival time Ti is equal to the corresponding po-
tential survival time Tj0i; on the other hand if the patient is observed to be a responder
and received treatment B1(B2), his/her observed survival time Ti is equal to the corre-
sponding counterfactual survival time T ∗j1i(T
∗
j2i), j = 1, 2. In the presence of right cen-
soring, the observed data can be summarized as the collection of i.i.d random vectors
{Ui,∆i, GHi (Ui)}, i = 1, · · · , n, where Ui = min(Ti, Ci),∆i = I(Ti ≤ Ci), Ci is the cen-
soring time and GHi (Ui) = {Zi, RiI(TRi ≤ x), XiRiI(TRi ≤ x), Vi(x), x ≤ u}, where Vi(x),
similar to the Vi defined before, is a vector of auxiliary variables that may additionally be
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collected on patient i at time x. Thus GHi (Ui) represents data-history collected on individ-
ual i prior to time u, which contains the information of the eligibility/consent status, the
time of response if responded, the assignment of maintenance treatment and other auxiliary
variables of interest of patient i.
Since in most clinical trials total follow-up time is limited, only restricted survival time
up to time L can be considered, where L is some value less than the maximum follow-up
time for all patients in the sample, in such cases, Tjk will actually represent min(Tjk, L).
The first goal of our research is to estimate and compare Sjk(t) for the policy AjBk,
j, k = 1, 2. Then, in the second part of the thesis, we develop a sample size formula for
testing the hypothesis H0 : F11(t) = F12(t) vs. H1 : F11(t) 6= F12(t) where F1k(t) =
Pr(T1k ≤ t) = E{I(T1k ≤ t)}, denotes the probability of failure before or at time t for
treatment strategy A1Bk, k = 1, 2. Furthermore, a supremum weighted log-rank test and
corresponding sample size formula are derived in order to compare the distributions of T11
and T21.
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3.0 A REVIEW OF INFERENTIAL PROCEDURES
3.1 INTRODUCTION
In this chapter, we review and compare the currently available inferential procedures for the
two-stage randomization designs with survival time as the primary outcome. Since the data
from patients receiving induction treatment A1 are independent of those from patients with
induction treatment A2, we focus only on the data from patients who received A1, that is,
patients with treatment policies A1B1 and A1B2. The methods for policies A2B1 and A2B2
follow analogously. Since we only consider the two treatment policies that are associated
with the induction treatment A1, we drop the subscript 1 in this chapter and chapter 4. For
instance, in these two chapters, Tki is short for T1ki, k = 1, 2.
3.2 AVAILABLE INFERENTIAL PROCEDURES
3.2.1 NAI¨VE ESTIMATOR
To estimate Sk(t) for the policy A1Bk, a na¨ıve approach would be to construct an estimator
only using the data from those patients who are treated consistently with that policy. If there
was no censoring, this would mean that one could average the indicator function I(Ti > t)
over all the patients in the set: {i : 1−Ri+RiXki = 1}, where X1i = Xi and X2i = 1−Xi,
to get
SˆNAI¨VEk (t) =
{
n∑
i=1
(1−Ri +RiXki)
}−1
×
n∑
i=1
(1−Ri +RiXki)I(Ti > t). (3.1)
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This na¨ıve estimator takes into account the patients who did not respond and those who were
assigned to maintenance treatment Bk. However, it neglects those patients who responded
and were randomized to treatment B3−k, k = 1, 2 , as a result, the na¨ıve estimator is expected
to underestimate Sk(t) by overestimating the contribution of the non-responders to the
survival distribution. Besides, the group of patients that has been used is no longer a
random sample from those who could potentially follow the policy A1Bk. In the cases where
their data is censored, Kaplan-Meier estimator for the survival distribution from the group
{i : 1−Ri +RiXki = 1} could be used to calculate the na¨ıve estimator.
3.2.2 CONSISTENT AND ASYMPTOTICALLY NORMAL ESTIMATORS
In order to make more efficient use of the information from patients who are inconsistent with
the policy A1Bk, Lunceford et al. [5] proposed three forms of consistent and asymptotically
normal estimators. Assume that the assignment of B treatment is conditionally independent
of the potential survival time given the induction treatment and the data collected prior
to observing the response. Let the probability of randomization to the B1-treatment be
denoted by pi1 = P (X1i = 1|Ri = 1). Then this assumption could be interpreted as X1i ⊥
T ∗1i, T
∗
2i|GHi (TRi ), Ri = 1. This, in turn, implies that Pr(X1i = 1|T ∗1i, T ∗2i, GHi (TRi ), Ri = 1) =
Pr(X1i = 1|Ri = 1) = pi1. This assumption is the “sequential randomization assumption”
or the assumption of “no unmeasured confounders” as discussed in Robins (1997). The
probability pik can be allowed to depend on the data-history prior to the randomization
including the induction treatment, but for simplicity, we avoid discussing it here. To be
consistent with the examples in chapter 1, we take pi1 to be known by design. Let us define
pi2 = 1 − pi1 = Pr(X1i = 0|Ri = 1) = Pr(X2i = 1|Ri = 1), where X2i = 1 − X1i. Let
K(u) = Pr(Ci > u) denote the survival distribution for the censoring time Ci. Assume also
that the censoring time is independent of the observed data and counterfactuals.
The first estimator in the sequel of three is defined as the weighted average of the patients
who are consistent with the treatment policy. Since by definition, non-responders are con-
sistent to the policy A1Bk, they were given unit weight in the construction. Responders who
were assigned to Bk with randomization probability pik are also consistent with the policy.
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But, due to the fact that some of the responders were randomized to the other B treatment,
each patient receiving Bk represents
1
pik −1 other similar patients who could have potentially
be assigned to B1 treatment, and thus received the weight
1
pik . Combining both, the weight
function takes the form Qki = 1 − Ri + RiXkipik , k = 1, 2. Additionally, since patients may
be censored at any time, a second form of weighting was applied to account for the censored
patients. Each uncensored patient with survival time Ui represents
1
K(Ui)
−1 prognostically
similar patients who survived beyond time Ui and thus receives a weight of
1
K(Ui)
. Thus
the combined weight for a patient with complete survival time Ui becomes
∆iQki
K(Ui)
. Since
K(u) is unknown, it is usually estimated by the Kaplan-Meier estimator of the censoring
survival curve Kˆ(U) =
∏
u≤t{1 − dN c(u)/Y (u)}, with N c(u) =
∑n
i=1 I(Ui ≤ u,∆i = 0)
and Y (u) =
∑n
i=1 I(Ui ≥ u), resulting in an estimated weight function ∆iQki/Kˆ(Ui). The
estimator for the survival function Sk(t) is then defined as:
SˆIPMWk (t) = 1− n−1
n∑
i=1
∆iQki
Kˆ(Ui)
I(Ui ≤ t), k = 1, 2. (3.2)
It was shown that if the true K(·) is substituted in the above equation, then SˆIPMWk (t) is
unbiased for Sk(t). Sˆ
IPMW
k (t) in equation (2) is an example of an inverse-probability-of-
missing-weighted (IPMW) estimator (Horvitz-Thompson estimator, Horvitz (1952)). The
second estimator was obtained by averaging using a probabilistically adjusted sample size,
i.e.,
SˆPAk (t) = 1−
{
n∑
i=1
∆iQki
Kˆ(Ui)
}−1 n∑
i=1
∆iQki
Kˆ(Ui)
I(Ui ≤ t), k = 1, 2 (3.3)
Lunceford et al. [5] observed that both SˆIPMWk (t) and Sˆ
PA
k (t) are solutions of the equations
of the form
∑n
i=1
∆i
Kˆ(Ui)
{QkiI(Ui ≤ t) + Sk(t) − 1 − αk(Qki − 1} = 0 with αk set to 0 and
1 − Sk(t), respectively. Thus the third estimator was constructed by choosing the αk that
minimizes the variance among all solutions. To be specific, the third estimator has the form:
SˆLDTk (t) = 1− n−1
n∑
i=1
∆iQki
Kˆ(Ui)
I(Ui ≤ t) + αˆkn−1
n∑
i=1
∆i
Kˆ(Ui)
(Qki − 1), k = 1, 2 (3.4)
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where
αˆk =
[
n−1
n∑
i=1
∆iQki(Qki − 1)I(Ui ≥ u)
Kˆ(Vi)
+
∫ L
0
dN c(u){Kˆ(u)Y (u)}−1Eˆ{Lα1k(t, u)}
]
÷
[
n−1
n∑
i=1
(Qki − 1)2 +
∫ L
0
dN c(u){Kˆ(u)Y (u)}−1Eˆ{Gαk (u)}
]
,
with
Eˆ{Lαk (t, u)} = n−1
n∑
i=1
∆i{QkiI(Ui ≤ t)− Gˆ1k(t, u)} × {Qki − 1− GˆQk(u)}
I(Ui ≥ u)
Kˆ(Ui)
,
Eˆ{Gαk (u)} = n−1
n∑
i=1
∆i{Qki − 1− GˆQk(u)}2
I(Ui ≥ u)
Kˆ(Ui)
,
GˆQk(u) = {nSˆk(u)}−1
n∑
i=1
∆i(Qki − 1)I(Ui ≥ u)
Kˆ(Ui)
,
Gˆ1k(u) = {nSˆk(u)}−1
n∑
i=1
∆iQkiI(Ui ≤ t)I(Ui ≥ u)
Kˆ(Ui)
.
The three estimators SˆIPMWk (t), Sˆ
PA
k (t) and Sˆ
LDT
k (t) are consistent and asymptotically nor-
mal. For details on the asymptotic property of these estimators we refer our readers to
Lunceford et al. [5]. These estimators were defined on an ad hoc basis and the formal
efficiency issue was not discussed.
3.2.3 SEMI-PARAMETRIC EFFICIENT ESTIMATOR
Wahed and Tsiatis [6] used the semi-parametric theory of missing data described in Robins,
Rotnitzky and Zhao [7] to characterize the most efficient regular asymptotically linear (RAL)
[17] estimator. They observed that any RAL estimator can be characterized by its influence
function and their approach was to find the most efficient influence function for all RAL
estimators of Sk(t). However, the most efficient influence function for this problem contains
a nuisance parameter in the form of the conditional expectation Pr(Tki > t|TRi , Vi, Ri =
1, Xki = 1). One way to construct useful estimators from the most efficient influence function
is to approximate these conditional probability based on patient data history leading to
locally efficient estimators. A natural way of estimating Pr(Tki > t|TRi , Vi, Ri = 1, Xki = 1)
13
is to use a logistic regression of the binary outcome I(Ti > t) on the covariates Vi and T
R
i
within the subgroup of patients with R = 1 and xk = 1. For instance, a logistic regression
model
Pr(Tki > t|TRi , Vi, Ri = 1, Xki = 1) =
1
1 + e−(γ0+γ1TRi +γT2 Vi)
= g(TRi , Vi; γ)
will give rise to the locally efficient estimator:
SˆLEk =
1
n
n∑
i=1
[{(1−Ri) + RiXki
pik
}I(Ui > t)−Ri(Xki − pik
pik
)g(TRi , Vi; γˆ)] (3.5)
for k = 1, 2. This estimator remains consistent even if the function form g(·) is not correctly
specified, but if the regression relationship was incorrectly specified, then the gain of efficiency
over the IPMW or LDT estimator could not be guaranteed. In the presence of right censoring,
an inverse probability weighted version of the locally efficient estimator (3.5) is given by
SˆIPCWLEk =
1
n
n∑
i=1
∆i
Kˆ(Ui)
[{
(1−Ri) + RiXki
pik
}
I(Ui > t)−Ri(Xki − pik
pik
)g(TRi , Vi; γˆ)
]
(3.6)
for k = 1, 2. We will refer to it as the Inverse Probability of Censoring Weighted Local
Efficient (IPCWLE) estimator. The properties of this estimator have not been investigated
in previous studies. This estimator is asymptotically unbiased. In addition, in our simulation
studies presented later, we find that the relative efficiency of this estimator over IPMW, PA
or LDT estimator is close to unity. But this estimator also depends on the specification of
the model g and therefore, is subjected to model mis-specification.
Wahed and Tsiatis [8] then extended the semi-parametric method to obtain the most
efficient estimator in the presence of right censoring. In order to avoid cumbersome calcula-
tion in the construction of most efficient estimator, they restricted the search for the optimal
estimator to a sub-class of the RAL estimators that contains the existing estimators. Let-
ting U∗i = min(Ci, T
R
i ), ∆
∗
i = I(Ci < T
R
i ), Yi(u) = I(Ui ≥ u), Eˆ1(u) =
∑n
i=1RiI(U
∗
i <
u)XkiYi(u)/Y (u), Eˆ2(u) = Y
−1(u)
∑n
i=1{1 − RiI(U∗i < u)}Yi(u) and L1i = {RiI(U∗i <
u)Xki − Eˆ1(u)}/pik, L2i = 1 − RiI(U∗i < u) − Eˆ2(u), a simplified version of the regular
asymptotic linear efficient (RALE) estimator is given by :
SˆRALEk (t) = An/Bn (3.7)
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where
An =
1
n
n∑
i=1
∆iQki
Kˆ(Ui)
I(Ui > t)− 1
n
n∑
i=1
∆∗i (Qki − 1)
Kˆ(U∗i )
γˆTWi
+
2∑
j=1
1
n
n∑
i=1
∫
dN ci (u)
Kˆ(u)
ϕˆj(u)Lji(u),
and
Bn =
1
n
n∑
i=1
∆iQki
Kˆ(Ui)
− 1
n
n∑
i=1
∆∗i (Qki − 1)
Kˆ(U∗i )
γˆTµWi
+
2∑
j=1
1
n
n∑
i=1
∫
dN ci (u)
Kˆ(u)
ϕˆjµ(u)Lji(u),
where γˆ = α−1β, γˆµ = −α−1βµ, ϕˆ1(u) = ζ−1(u)η(u), ϕˆ1µ(u) = 1, ϕˆ2(u) = κ−1(u)τ(u),
ϕˆ2µ(u) = κ
−1(u)− τµ(u) where,
α = n−1
n∑
i=1
∆i
Kˆ(Ui)
{
K−1(U∗i )(Qki − 1)2W iW Ti
}
,
β = n−1
n∑
i=1
∆i
Kˆ(Ui)
{
K−1(U∗i )Qki(Qki − 1)I(Ui > t)W i
}
,
βµ = n
−1
n∑
i=1
∆i
Kˆ(Ui)
{
K−1(U∗i )Qki(Qki − 1)W i
}
,
τ(u) = n−1
n∑
i=1
∆i
Kˆ(Ui)
[{
(1−Ri)I(U∗i ≥ u) +
RiXki
pi
}
I(Ui > t)
]
,
τµ(u) = n
−1
n∑
i=1
∆i
Kˆ(Ui)
{
(1−Ri)I(U∗i ≥ u) +
RiXki
pi
}
,
κ(u) = n−1
n∑
i=1
∆i
Kˆ(Ui)
[
I(Ui ≥ u)
{
1−RiI(TRi < u)
}]
,
η(u) = n−1
n∑
i=1
∆i
Kˆ(Ui)
{I(U∗i < u ≤ Ui)RiXkiI(Ui > t)} ,
ζ(u) = n−1
n∑
i=1
∆i
Kˆ(Ui)
{I(U∗i < u ≤ Ui)RiXki} .
The estimator SˆRALEk is consistent and asymptotically normaland is guaranteed to be asymp-
totically more efficient than the IPMW and LDT estimators since it is the most efficient
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estimator among a class of estimators including the IPMW and LDT estimators. For details
on the proof of asymptotic properties, variance estimates, and the estimates of covariance
between SˆRALE1 (t) and Sˆ
RALE
2 (t), we refer the readers to Wahed and Tsiatis [8].
3.2.4 WEIGHTED RISK SET ESTIMATOR
Guo and Tsiatis [10] derived the Weighted Risk Set Estimator (WRSE) using the concepts
of counting process and risk sets, which is an extension of the Aalen-Nelson estimator. This
estimator is more intuitive and easier to compute than the above ones. The intention was to
use Aalen-Nelson estimator to estimate the cumulative hazard function, however, due to the
property of two stage design, not all counting processes Ni(u) = I(Ui ≤ u,∆i = 1) and at risk
process Yi(u) = I(Ui ≥ u) could be observed, because some of the patients who could have
received treatment B1 are instead randomized to receive B2. Consequently, a time-varying
weight function was defined for treatment strategy A1B1: Wi(u) = 1−Ri(u) +Ri(u)Xi/pi1,
where Ri(u) = RiI(T
R
i ≤ u) is the indicator of response at time u for patient i. With
this weight function, the extended Aalen-Nelson estimator for the cumulative hazard under
policy A1B1 is defined as
∆ˆ1(t) =
∫ t
0
∑n
i=1Wi(u)dNi(u)∑n
i=1Wi(u)Yi(u)
(3.8)
and the corresponding estimator for the survival function follows as
SˆWRSE1 (t) = exp
{
−
∫ t
0
∑n
i=1Wi(u)dNi(u)∑n
i=1Wi(u)Yi(u)
}
(3.9)
It has been shown that WRSE is consistent and asymptotically normal. Detailed proof of
the consistency and asymptotically normality of the WRSE is given by Guo and Tsiatis [10].
3.2.5 COX PROPORTIONAL HAZARD MODEL
Because of the wide use of Cox regression model in the analysis of survival data, Lokhny-
gina and Helterbrand [9] derived a consistent estimator for the log hazard ratio comparing
strategies A1B1 and A2B1 in the Cox model. In addition to the sequential randomization
assumption and the assumption of independent censoring, this construction like other appli-
cations using Cox model, requires the proportional hazard assumption between two treatment
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policies. As in a usual Cox proportional hazard model, consider the hazard corresponding
to policy A2−jB1 be λ(t|Z = j), j = 0, 1 where λ(t|Z) = λ0(t)exp(Zβ), The estimate of β
can be obtained by solving the pseudo-score equation
Uwn(β) =
n∑
i=1
∫ ∞
0
wi{Zi − Z¯w(u, β)}dNi(u) = 0 (3.10)
where wi = 1−Ri +Ri(u)Xi/pi1 acts as an inverse probability weight, and
Z¯w(u, β) =
∑n
i=1wiZiYi(u)exp(Ziβ)∑n
i=1wiYi(u)exp(Ziβ)
.
Lokhnygina and Helterbrand [9] showed that the estimator of β is consistent and asymptot-
ically normal. This estimator is easier to implement with available software and intuitively
appealing.
3.3 SIMULATION STUDIES
To evaluate the performance of the methods reviewed in the previous section, several simu-
lations were carried out following Lunceford et al. [5] strategy. We only simulated data
for policy AB1 and AB2 since the data from A1 and A2 are independent. All simula-
tions were based on a 2.5-year study for n=200 and 500 subjects. For each individual,
censoring time C was generated as uniform(0,2.5) independent of all other variables. Remis-
sion/consent status R were sampled from Bernoulli(piR). Two values of the response rate
piR = 0.4 and piR = 0.6 were used in this simulation. The B treatment indicators were
generated from Bernoulli(0.5) distribution. For non-responders (R = 0), a survival time T ∗λ
was generated from exponential(λ), where λ was taken to be 2.22 so that E(T ∗λ )/L = 0.3,
where L = 1.5 was the upper limit of the restricted observed lifetime. For responders, a
remission/consent time TR was drawn from exponential(α). We take T ∗∗1 ∼ EXP (eβ1),
T ∗∗2 ∼ EXP (eβ1+β2T ∗∗1 ), where T ∗∗1 and T ∗∗2 are post-remission survival time under B1 and
B2, respectively. The parameters α, β1 and β2 were chosen to be 6.67, 0.29 and -0.67, re-
spectively, so that E(TR)/L = 0.1, E(T ∗∗1 )/L = 0.5, and E(T
∗∗
2 )/L = 1.0. The potential
restricted survival times were calculated as T1 = min{(1 − R)T ∗λ + R(TR + T ∗∗1 ), L} and
T2 = min{(1−R)T ∗λ +R(TR + T ∗∗2 ), L}.
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Table 3.1: Monte Carlo means, relative biases (bias as a percentage of the true value) and mean squared errors (MSE, expressed
as multiples of 103) for estimation of survival probabilities based on 1000 data sets of sizes 200 each. The true values were
S1(0.5) = 0.450, S2(0.5) = 0.492, S1(1.0) = 0.196, S2(1.0) = 0.261 for 40% response and S1(0.5) = 0.511, S2(0.5) = 0.575,
S1(1.0) = 0.240, S2(1.0) = 0.339 for 60% response.
piR = 0.4 piR = 0.6
Policy AB1 Policy AB2 Policy AB1 Policy AB2
t(years) Estimator Sˆ(t) Bias(%) MSE Sˆ(t) Bias(%) MSE Sˆ(t) Bias(%) MSE Sˆ(t) Bias(%) MSE
0.5 IPMW 0.452 0.4 4.28 0.493 0.2 4.42 0.511 0.0 5.48 0.578 0.5 5.93
PA 0.450 0.0 2.44 0.492 0.0 2.38 0.511 0.0 2.73 0.575 0.0 2.56
LDT 0.447 0.7(-) 2.11 0.489 0.6(-) 2.00 0.508 0.6(-) 2.41 0.571 0.7(-) 2.23
IPCWLE 0.450 0.0 2.18 0.492 0.0 2.03 0.510 0.2(-) 2.51 0.574 0.2(-) 2.27
WRSE 0.453 0.7 1.91 0.495 0.6 1.93 0.514 0.6 2.20 0.578 0.5 2.15
RALE 0.446 0.9(-) 2.07 0.489 0.6(-) 1.98 0.508 0.6(-) 2.35 0.572 0.5(-) 2.18
1.0 IPMW 0.197 0.5 2.84 0.263 0.8 3.58 0.239 0.4 3.84 0.341 0.6 4.81
PA 0.196 0.0 2.29 0.262 0.4 2.65 0.238 0.8(-) 2.93 0.338 0.2(-) 3.17
LDT 0.193 1.5 2.03 0.259 0.8(-) 2.20 0.237 1.3(-) 2.62 0.335 1.2(-) 2.75
IPCWLE 0.194 1.0(-) 2.13 0.261 0.0 2.36 0.238 0.8(-) 2.72 0.337 0.6(-) 2.92
WRSE 0.200 2.0 1.71 0.267 1.5 2.00 0.243 1.3 2.25 0.343 1.2 2.53
RALE 0.192 2.0(-) 1.87 0.259 0.8(-) 2.09 0.236 1.7(-) 2.41 0.336 0.9(-) 2.60
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Table 3.2: Monte Carlo means, relative biases (bias as a percentage of the true value) and mean squared errors (MSE, expressed
as multiples of 103) for estimation of survival probabilities based on 1000 data sets of sizes 500 each. The true values were
S1(0.5) = 0.450, S2(0.5) = 0.492, S1(1.0) = 0.196, S2(1.0) = 0.261 for 40% response and S1(0.5) = 0.511, S2(0.5) = 0.575,
S1(1.0) = 0.240, S2(1.0) = 0.339 for 60% response.
piR = 0.4 piR = 0.6
Policy AB1 Policy AB2 Policy AB1 Policy AB2
t(years) Estimator Sˆ(t) Bias(%) MSE Sˆ(t) Bias(%) MSE Sˆ(t) Bias(%) MSE Sˆ(t) Bias(%) MSE
0.5 IPMW 0.451 0.2 1.54 0.494 0.4 1.71 0.512 0.2 2.10 0.576 0.2 2.23
PA 0.451 0.2 0.95 0.493 0.2 0.94 0.512 0.2 1.05 0.575 0.0 0.97
LDT 0.450 0.0 0.85 0.492 0.0 0.79 0.511 0.0 0.92 0.574 0.2(-) 0.85
IPCWLE 0.450 0.0 0.85 0.493 0.2 0.80 0.511 0.0 0.97 0.576 0.2 0.85
WRSE 0.452 0.4 0.77 0.494 0.4 0.79 0.513 0.4 0.85 0.576 0.2 0.81
RALE 0.450 0.0 0.78 0.492 0.0 0.78 0.511 0.0 0.87 0.574 0.2(-) 0.82
1.0 IPMW 0.197 0.0 1.07 0.263 0.8 1.36 0.241 0.4 1.50 0.341 0.6 1.89
PA 0.197 0.0 0.88 0.263 0.8 1.03 0.241 0.4 1.14 0.340 0.3 1.27
LDT 0.196 0.0 0.80 0.262 0.4 0.87 0.240 0.0 1.02 0.339 0.0 1.11
IPCWLE 0.197 0.5 0.87 0.263 0.8 0.89 0.241 0.4 1.09 0.340 0.3 1.14
WRSE 0.199 1.5 0.68 0.264 1.2 0.82 0.243 1.3 0.88 0.342 0.9 1.01
RALE 0.197 0.5 0.69 0.262 0.8 0.81 0.241 0.4 0.89 0.339 0.0 1.01
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For each of 1000 Monte Carlo data sets, P (Tk) > t, k = 1, 2 were estimated at time
point 0.5 year and 1.0 year, reflecting early and late period of study. The mean squared
errors were calculated from the bias of the estimated mean probability and the variance of
the 1000 estimates. In calculating the IPCWLE and RALE estimators, the response time TRi
was considered as the only auxiliary variable which the survival time could depend upon. For
IPCWLE, to model the conditional expectation of survival probability among the responders
who are consistent with the policy, logistic regression of survival probability on the response
time was fitted. We did not include the Lokhnygina and Helterbrand’s [9] Cox regression
method in our simulation because its distinct property makes comparison less feasible.
Table 3.1 presents the mean, relative bias and mean squared errors for survival probability
estimates based on 1000 samples of size 200 each. As shown in Table 1, almost all the relative
biases, calculated as (bias/true value)×100, were less than 2%. By closely examining the
table we notice that the relative biases were larger for t = 1.0 than t = 0.5, that is, the
estimators were more biased for survival estimates at times towards the end of the study
when there were more censoring present. In comparing the biases of different estimators in
small samples, the PA estimator was generally the least biased, followed by the IPCWLE
and IPMW estimators. LDT and RALE estimators always underestimated the true values
whereas WRSE estimator overestimated them.
Comparing the MSE’s, IPMW estimates were the least efficient as one would expect
since no information from the censored patients or any auxiliary information is used in
construction of such estimator. Among the IPMW, PA, LDT and RALE estimates whose
influence functions belong to the same class, LDT estimates showed substantial gains in
efficiency relative to both the first two, and RALE estimates are more efficient than LDT
estimates in all scenarios, with the relative efficiency ranging from 1.01 to 1.18. The MSE
of IPCWLE estimates were slightly larger than that of LDT estimates but substantially
smaller than that of IPMW or PA estimates. In most instances WRSE estimator appeared
to be the most efficient among all the estimates. The relative efficiencies of WRSE estimates
with respect to LDT estimates ranged from 1.00 to 1.19 and the gain is bigger when more
censoring is present. In general, the MSEs followed the pattern: IPMW ≥ PA ≥ IPCWLE
≥ LDT ≥ RALE ≥ WRSE.
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Table 3.2 presents the mean, relative bias and mean squared errors for survival probability
estimates based on 1000 samples of size 500 each. When the sample size was increased to 500,
all the biases dropped to less than 1% except for the WRSE estimator. It was not surprising
since the asymptotic unbiasness of WRSE estimator is achieved via the exponential functional
of the cumulative hazard function. When the sample size was increased from 200 to 500,
the efficiency of all the estimators improved, but the trend of relative efficiencies remained
mostly unaffected.
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4.0 INVERSE-PROBABILITY-WEIGHTING BASED SAMPLE SIZE
FORMULA
4.1 BACKGROUND AND OBJECTIVE
Suppose the goal is to test the hypothesis that the probability of survival under a given strat-
egy at a fixed time t does not differ from that under a different strategy sharing the same
initial treatment. The goal can be accomplished by comparing the consistent estimators of
survival probabilities under both strategies. Let us consider the IPMW estimator defined in
3.2.2 for this purpose. This inverse-probability weighting estimators are constructed based on
the patients who actually received the combined treatments and those who did not respond
to the initial treatment or those who refused further treatment. Thus when comparing the
survival under two treatment strategies sharing the same initial treatment, the pair of esti-
mators are not independent, since they are influenced by the same set of non-responders and
non-consenters. In other words, the two groups of patients that are used to estimate survival
are no longer random samples from those who could potentially follow respective treatment
strategies. Consequently, one can not use the usual two-sample sample size formula for com-
paring the survival rates between two independent groups. In this section, the primary goal
is to determine the required sample size for testing the hypothesis H0 : F1(t) = F2(t) vs.
H1 : F1(t) 6= F2(t) where Fk(t) = Pr(Tk ≤ t) = E{I(Tk ≤ t)}, denotes the probability
of failure before or at time t for treatment strategy A1Bk, k = 1, 2. We derive a sample
size formula based on Lunceford et al.’s [5] estimator which is appropriate for censored data
and sequential randomization. In other words, Fˆk(t) = 1− Sˆk(t), where Sˆk(t) was shown in
equation (3.3).
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Following the appendix in Lunceford et al. [5] , we have the large-sample property
n1/2{Fˆk(t)− Fk(t)} = n−1/2
n∑
i=1
ψki + op(1), (4.1)
where ψki is the influence function for Fˆk(t), given by
ψki = Qki{I(Ti ≤ t)− Fk(t)} −
∫ L
0
Qki{I(Ti ≤ t)− Fk(t)} −G1k(t, u)
K(u)
dM ci (u), (4.2)
where
Gk(t, u) =
E[{I(Tki ≤ t)− Fk(t)}I(Tki ≥ u)]
P (Ti > u)
, (4.3)
λc(u) is the hazard function for the censoring distribution, and M ci (t) is the corresponding
martingale process [11] M ci (t) = N
c
i (t) −
∫ t
0
λc(u)Yi(u)du, where N
c
i (t) = I(Ui ≤ t,∆i = 0)
and Yi(u) = I(Ui ≥ u). The variance of the influence function is given by
σ2ψk = E(ψki)
2 = E[Qki{I(Ti ≤ t)− Fk(t)}]2 +
∫ L
0
E{Lki(t, u)}2
K(u)
λc(u)du, (4.4)
where Lki(t, u) = [Qki{I(Ti ≤ t) − Fk(t)} − Gk(t, u)]I(Ti ≥ u). Similarly, the covariance of
ψ1i and ψ2i is
σψ1ψ2 = E(ψ1iψ2i) = E[Q1iQ2i{I(Ti ≤ t)− F1(t)}
× {I(Ti ≤ t)− F2(t)}] +
∫ L
0
E{L1i(t, u)L2i(t, u)}
K(u)
λc(u)du. (4.5)
For details on the derivation of (4.4) and (4.5) we refer the reader to Lunceford et al. [5].
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4.2 A SAMPLE SIZE FORMULA FOR TESTING EQUALITY OF
SURVIVAL PROBABILITIES
Denoting F1(t)−F2(t) by D, our goal is to test the null hypothesis H0 : D = 0 against HA :
D 6= 0. Utilizing the fact that the above estimators are consistent and asymptotically normal,
the hypothesis testing could be performed using Wald’s test with the test statistic being
Z = Dˆ/σˆD, where Dˆ = Fˆ1(t)− Fˆ2(t) and σˆ2D is a consistent estimator of the variance of Dˆ,
σ2D. Since Fˆ1(t) and Fˆ2(t) are asymptotically normally distributed, Z is also asymptotically
follow the standardized normal distribution under the null hypothesis. A consistent estimator
of σ2D can be obtained by using the formula for variance and covariance estimates given in
Lunceford et al. [5]. However, for power or sample size calculation in the absence of pilot
data, one needs to have knowledge about the actual variance σ2D.
By (4.1), the asymptotic variance of Fˆk(t) is given by var(Fˆk(t)) = E(ψ
2
k)/n = σ
2
ψk
/n,
and consequently, the asymptotic variance of Dˆ is
σ2D = var(Dˆ) = σ
2
ψ1−ψ2/n =
σ2ψ1 + σ
2
ψ2
− 2σψ1ψ2
n
. (4.6)
If the variabilities σ2ψ1 , σ
2
ψ2
and σψ1ψ2 were known with type I error set to α, the true difference
in survival probabilities at time t, D, can be detected with pre-specified power 1− β, when
the sample size is at least
n =
σ2ψ1−ψ2 · (z1−α/2 + z1−β)2
D
, (4.7)
where z1−α/2 and z1−β are the 100(1 − α/2)th and 100(1 − β)th percentile of the standard
normal distribution, respectively. But σ2ψ1 , σ
2
ψ2
and σψ1ψ2 are unknown and hence educated
guess should be made regarding them in order to use the above sample size formula. However,
expressions (4.4) and (4.5) are too complicated. Our purpose is to express equations (4.4)
and (4.5) in simplified forms in terms of the parameters of the survival distributions of sub-
populations. Let us denote the cumulative distributions of the counterfactual variables T0,
T ∗1i and T
∗
2i by F0, F
∗
1 and F
∗
2 , and the corresponding survival functions by S0, S
∗
1 and S
∗
2 ,
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respectively. For k = 1, the first term on the right side of (4.4) can be rewritten as
E{Q21i[I(T1i ≤ t)− F1(t)]2} = E[{I(T1i ≤ t)− F1(t)}2E(Q21i|T1i)]
= [V ar(I(T1i ≤ t))] · (1− piR + piR/pi1)
= F1(t)(1− F1(t))(1− piR + piR/pi1), (4.8)
where F1(t) = P(T1i ≤ t) = (1− piR)F0(t) + piRF ∗1 (t), and piR = P(Ri = 1).
For the other term in (4.4), since L1i(t, u) = [Q1i{I(Ti ≤ t)−F1(t)}−G1(t, u)]I(Ti ≥ u),
we have
E{L1i(t, u)}2 = E
[
Q21i{I(Ti ≤ t)− F1(t)}2I(Ti ≥ u)
− 2Q1i{I(Ti ≤ t)− F1(t)}G1(t, u)I(Ti ≥ u)
+ G21(t, u)I(Ti ≥ u)
]
. (4.9)
Using the fact that E(Q21i|T1i) = 1− piR + piR/pi1, the first part in equation (4.9) can be
written as
E
[
Q21i{I(T1i ≤ t)− F1(t)}2I(T1i ≥ u)
]
= E
[
Q21iI(T1i ≤ t)I(T1i ≥ u)− 2Q21iI(T1i ≤ t)F1(t)I(T1i ≥ u) +Q21iF 21 (t)I(T1i ≥ u)
]
= E
[
I(u ≤ T1i ≤ t)E(Q21i|T1i)
]− 2F1(t)E [I(u ≤ T1i ≤ t)E(Q21i|T1i)]
+F 21 (t)E
[
I(T1i ≥ u)E(Q21i|T1i)
]
= (S1(u)− S1(t))(1− piR + piR/pi1)− 2F1(t)(S1(u)− S1(t))(1− piR + piR/pi1)
+F 21 (t)S1(u)(1− piR + piR/pi1)
= (1− piR + piR/pi1)[F1(t)− F1(u)− 2F1(t)(F1(t)− F1(u)) + F 21 (t)S1(u)]. (4.10)
Similarly, since E(Q1i|T1i) = 1, the second part in (4.9) is :
−2G1(t, u)E [{I(u ≤ T1i ≤ t)− I(T1i ≥ u)F1(t)}E(Q1i|T1i)]
= −2G1(t, u) [S1(u)− S1(t)− (1− S1(t))S1(u)]
= 2G1(t, u)S1(t)F1(u). (4.11)
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The third part in (4.9) is :
G21(t, u)E[I(Ti ≥ u)]
= G21(t, u) [(1− piR)S0(u) + piR{pi1S∗1(u) + (1− pi1)S∗2(u)}] . (4.12)
Thus adding (4.10), (4.11), and (4.12)
E{L1i(t, u)}2 = (1− piR + piR/pi1)[F1(t)− F1(u)− 2F1(t)(F1(t)− F1(u)) + F 21 (t)S1(u)]
+2G1(t, u)S1(t)F1(u)
+G21(t, u) [(1− piR)S0(u) + piR{pi1S∗1(u) + pi2S∗2(u)}] , (4.13)
where
Gk(t, u) =
E[I(Tki ≤ t)I(Tki ≥ u)− Fk(t)I(Tki ≥ u)
P (Ti ≥ u)
=
(Sk(u)− Sk(t))− (1− Sk(t))Sk(u)
P (Ti ≥ u) =
−Sk(t)Fk(u)
P (Ti ≥ u) ,
P (Ti ≥ u) = (1−piR)S0(u)+piR {pi1S∗1(u) + pi2S∗2(u)}), and S1(t) = (1−piR)S0(t)+piRS∗1(t).
Thus, given the censoring distribution, the variance of ψ1i can be explicitly expressed by
σ2ψ1 = F1(t)(1− F1(t))(1− piR + piR/pi1) +
∫ L
0
(4.13)× λc(u)
K(u)
du. (4.14)
The variance of ψ2i, σ
2
ψ2
can be derived analogically. Now in order to obtain the variance
of ψ1i − ψ2i, we need to simplify the covariance term in equation (4.5).
It can easily be shown that E(Q1iQ2i|T1i, T2i) = 1 − piR, leading the first term in the
right side of (4.5) to
E [Q1iQ2i{I(Ti ≤ t)− F1(t)}{I(Ti ≤ t)− F2(t)}]
= E [Q1iQ2i{I(T1i ≤ t)− F1(t)}{I(T2i ≤ t)− F2(t)}]
= E [{I(T1i ≤ t)I(T2i ≤ t)− F1(t)F2(t)}E(Q1iQ2i|T1i, T2i)]
= E [I(T1i ≤ t)I(T2i ≤ t)− F1(t)F2(t)] (1− piR). (4.15)
26
If we assume that T ∗1i ⊥ T ∗2i|R = 1, then E [I(T1i ≤ t)I(T2i ≤ t)] in (4.15) can be expressed
as
E [I(T1i ≤ t)I(T2i ≤ t)]
= P [I(T1i ≤ t)I(T2i ≤ t)|R = 1]P (R = 1) + P [I(T1i ≤ t)I(T2i ≤ t)|R = 0]P (R = 0)
= piRF
∗
1 (t)F
∗
2 (t) + (1− piR)F0(t). (4.16)
We substitute equation (4.16) into (4.15), then the first term in the right side of (4.5)
becomes
piR(1− piR)F ∗1 (t)F ∗2 (t) + (1− piR)2F0(t)− (1− piR)F1(t)F2(t) (4.17)
For the second part of (4.5), using derivations similar to (4.10), (4.11), and (4.12), we obtain
E{L1i(t, u)L2i(t, u)} = {(1− F1(t)− F2(t))(F0(t)− F0(u)) + F1(t)F2(t)(1− F0(u))} (1− piR)
−G2(t, u){−F1(u)S1(t)} −G1(t, u){−F2(u)S2(t)}
+G1(t, u)G2(t, u) [(1− piR)S0(u) + piR(pi1S∗1(u) + pi2S∗2(u))] . (4.18)
Thus the covariance σψ1ψ2 between ψ1i and ψ2i in equation (4.5) is given by
σψ1ψ2 = (4.17) +
∫ L
0
(4.18)
K(u)
λc(u)du. (4.19)
Finally, the variance of ψ1i − ψ2i is
σ2ψ1−ψ2 = σ
2
ψ1i
+ σ2ψ2i − 2σψ1ψ2 . (4.20)
Thus if we make working distributional assumptions for T0, T
∗
1 , T
∗
2 , and make clinically
meaningful estimates of the remission/consent rate piR and the censoring distribution, given
the randomization rate pi1, we would be able to calculate the variance σ
2
ψ1−ψ2 and hence
determine the sample size using (4.7). If T0, T
∗
1 and T
∗
2 are assumed to follow exponential
distributions (irrespective of what the true distributions are), then the required distributional
forms of T0, T
∗
1 and T
∗
2 are identified by the means of T0, T
∗
1 and T
∗
2 respectively, making
computations simpler. We will compute the variance and the sample sizes based on the
working assumption that the counterfactual survival times are exponentially distributed and
will check the sensitivity of this assumption by generating samples from other distributions.
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~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
H0: F11( 1 )= F12( 1 )= 0.65
Ha: F11( 1 )= 0.65 , F12( 1 )= 0.45
Type I error: 0.05
Power : 0.8
Required Sample Size for the A1 arm: 188
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Figure 4.1: A snapshot of the output generated by the R routine for sample size.
Generally, the censoring time is assumed to follow a uniform distribution over some
interval [0, τ ], where τ is some time point beyond the length of the trial. We will adopt
this assumption for the purpose of illustration. For this special case, C ∼ UNIF(0, τ),
K(u) = 1 − u/τ and λc(u) = 1/(τ − u). Other censoring distributions such as exponential
censoring can also be implemented. We have developed an R [18] routine to calculate the
sample size based on the proposed variance formula (see Appendix A.1). Figure 4.1 gives a
snapshot of the output generated by the routine.
4.3 SIMULATION STUDIES
To evaluate the performance of the sample size formula proposed above, several simulations
were carried out. We only simulated data for strategy A1B1 and A1B2. All simulations
were based on a 2.5 year study, with the upper limit of the restricted observed lifetime
being 1.5 years. For each individual, censoring time C was generated from a UNIF(0,3.5)
independent of all other variables, resulting in 18% to 24% censoring at the end of one year.
Remission/consent status R were sampled from and Bernoulli(0.5) in Table 4.1 and from
Bernoulli(0.7) in Table 4.2. The B treatment indicators were generated from Bernoulli(0.5)
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distribution, i.e, for those who responded and agreed to further treatment, the randomization
ratio between the two maintenance treatments was 1:1.
In the simulation scenarios described in Table 4.1 and Table 4.2, for nonresponders (R =
0), a survival time T0 was drawn from EXP(α0). For responders, we take T
∗
1 ∼ EXP (α1),
T ∗2 ∼ EXP (α2), where T ∗1 and T ∗2 are survival time for patients treated with B1 and B2,
respectively. For each of the two response rate scenarios, specific values of α0, α1 and α2
were chosen so that when F1(1.0) = 0.65, F2(1.0) varies from 0.55 to 0.35, similarly, when
F1(1.0) = 0.50, F2(1.0) varies from 0.43 to 0.25. As a result, the difference in survival
probability D to be detected ranged from 0.08 to 0.30. The potential restricted survival
times were calculated as T1 = min{(1−R)T ∗0 +RT ∗1 , L} and T2 = min{(1−R)T ∗0 +RT ∗2 , L}.
For the purpose of sample size determination, the variance σ2ψ1−ψ2 was calculated using
equation (4.20) under the true assumption of exponential survival distributions (we check
the sensitivity of this assumption in simulation scenarios presented later). The sample size
n was then determined by the sample size formula (4.7) be setting α = 0.05 and β = 0.20.
We generated 2000 Monte-Carlo samples of size n from the true survival distributions. For
each of these samples the test statistic Z = Dˆ/σˆD was computed and compared to the null
distribution. The observed power was calculated as the proportions of Monte Carlo data sets
for which the null hypothesis was rejected at the .05 type I error level. For each scenario,
data from null distributions, i.e, when the F2(1.0) was actually the same as F1(1.0), were
also generated to assess the false rejection rates (type I error).
Results presented in Table 4.1 and Table 4.2 show that the sample sizes obtained using
the proposed sample size formula provided observed power that are close to the expected
power. In a few occasion, for smaller true differences in survival, average observed powers
were smaller than the expected power. The test always maintained the nominated type I
error level.
In practice, however, the distribution of true survival are unknown and thus the working
assumption of the underlying survival distributions being exponential may not be valid.
Simulations were also carried out where the true survival times were generated from log-
normal, Weibull or a mixture of log-normal and Weibull distributions to assess the robustness
of our sample size formula to the mis-specification of true distributions. The parameters of
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Table 4.1: Sample size and achieved power for comparing survival probabilities at 1.0 year
using inverse-probability-weighted estimator. Results are from simulation studies based on
2000 Monte Carlo data sets. Survival times for non-responders, responders in treatment
strategy A1B1, and responders in A1B2 are generated from exponential distributions with
means α0,α1 and α2, respectively. Response rate is assumed to be 50%, randomization ratio
is 1:1 for the B-treatment.
α0 α1 α2 F1(1.0) F2(1.0) Var(ψ1 − ψ2) n power Type I error
0.825 1.10 1.64 0.65 0.58 0.7339 1166 0.780 0.056
0.825 1.10 1.98 0.65 0.55 0.7399 578 0.774 0.056
0.825 1.10 2.83 0.65 0.50 0.7438 261 0.775 0.051
0.925 0.98 3.66 0.65 0.45 0.7408 146 0.792 0.047
0.965 0.94 5.94 0.65 0.40 0.7321 92 0.805 0.052
1.054 2.04 3.52 0.50 0.43 0.7365 1177 0.817 0.050
1.054 2.04 4.83 0.50 0.40 0.7245 566 0.813 0.042
1.268 1.65 5.96 0.50 0.35 0.7107 248 0.849 0.046
2.262 0.97 3.59 0.50 0.30 0.7059 139 0.867 0.054
2.262 0.97 6.50 0.50 0.25 0.6768 85 0.887 0.056
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Table 4.2: Sample size and achieved power for comparing survival probabilities at 1.0 year
using inverse-probability-weighted estimator. Results are from simulation studies based on
2000 Monte Carlo data sets. Survival times for non-responders, responders in treatment
strategy A1B1, and responders in A1B2 are generated from exponential distributions with
means α0,α1 and α2, respectively. Response rate is assumed to be 70%, randomization ratio
is 1:1 for the B-treatment.
α0 α1 α2 F1(1.0) F2(1.0) σ
2
ψ1−ψ2 n power Type I error
0.545 1.19 1.80 0.65 0.55 0.9591 760 0.720 0.045
0.545 1.19 2.29 0.65 0.50 0.9612 335 0.775 0.049
0.545 1.19 3.01 0.65 0.45 0.9540 188 0.771 0.051
0.545 1.19 4.21 0.65 0.40 0.9376 118 0.792 0.057
0.545 1.19 6.63 0.65 0.35 0.9122 80 0.772 0.051
0.855 1.84 2.61 0.50 0.43 0.9630 1513 0.805 0.052
0.855 1.84 3.10 0.50 0.40 0.9502 739 0.792 0.053
0.855 1.84 4.37 0.50 0.35 0.9220 321 0.790 0.052
0.855 1.84 7.01 0.50 0.30 08850 173 0.817 0.059
0.855 1.84 15.72 0.50 0.25 0.8397 106 0.844 0.061
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Table 4.3: Achieved power when comparing survival probabilities at 1.0 year using inverse-
probability-weighted estimator. Simulation studies were based on 2000 Monte Carlo data
sets. Survival times for nonresponders, responders in treatment strategy A1B1, and re-
sponders in A1B2 were generated from log-normal distributions in Scenario 1, from Weibull
distributions in Scenario 2. In Scenario 3, the distributions for the three survival times T0, T
∗
1
and T ∗2 are generated from exponential, log-normal and Weibull distribution, respectively.
Sample sizes are based on the assumption that the survival times were from exponential
distributions.
Power(Type I error)
piR F1(1.0) F2(1.0) n Scenario 1 Scenario 2 Scenario 3
0.70 0.65 0.55 760 0.736(0.052) 0.793(0.050) 0.748(0.056)
0.65 0.50 335 0.750(0.054) 0.771(0.048) 0.739(0.052)
0.65 0.45 188 0.770(0.055) 0.795(0.053) 0.755(0.067)
0.65 0.40 118 0.745(0.051) 0.772(0.051) 0.748(0.068)
0.65 0.35 80 0.776(0.060) 0.789(0.046) 0.789(0.065)
0.50 0.50 0.43 1177 0.816(0.049) 0.814(0.046) 0.823(0.051)
0.50 0.40 566 0.806(0.050) 0.821(0.050) 0.801(0.047)
0.50 0.35 248 0.812(0.047) 0.824(0.051) 0.820(0.049)
0.50 0.30 139 0.841(0.048) 0.832(0.043) 0.816(0.059)
0.50 0.25 85 0.826(0.051) 0.841(0.057) 0.818(0.057)
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these distributions were chosen such that the expected probabilities of survival at time 1.0
(year) is the same as those in tables 4.1 and 4.2. Table 4.3 shows that when we use the sample
size formula as if the survival times were from exponential distributions, the observed power
remains close to the expected power (0.80). For observed type I errors, they were again
around 0.05, similar to the results presented in tables 4.1 and 4.2. In other words, the
working assumption of exponential true survival played no major role in the variance and
hence sample size calculation. Thus, as long as we know the means of T0, T
∗
1 and T
∗
2 ,
we can ignore the true underlying distributions and calculate the variance as though the
true counterfactuals followed exponential distributions. The implication of this finding is
that when planning a two stage randomization clinical trial to test the equality of survival
between two strategies sharing the same induction treatment, we only need to know the
means of T0, T
∗
1 and T
∗
2 , regardless of their actual distributions.
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5.0 SUPREMUM WEIGHTED LOG-RANK TEST AND
CORRESPONDING SAMPLE SIZE
5.1 INTRODUCTION
In the previous chapter we have considered testing the equality of two treatment strategies
based on survival probabilities at fixed time t. However, survival probabilities at a fixed
time t may not reflect the overall nature of the design. For the purpose of comparing overall
survival pattern under various treatment strategies, Guo [12] proposed a weighted log-rank
test, which was pointed out to have low power for detecting time-varying relative hazards[13].
In this chapter, we define a supremum weighted log-rank test for testing the equality of
two adaptive treatment strategies sharing same maintenance treatment based on the overall
survival distributions. Another important problem that we will address in this chapter is the
determination of sample size to detect a particular class of alternatives. We derive a sample
size formula based on the proposed supremum weighted log-rank statistic and conduct power
analysis through simulation.
We will focus on comparing the survival distributions of treatment strategies A1B1 and
A2B1, i.e., to compare the distributions of T11 and T21. The method for comparing other
pairs of treatment strategies follows analogously.
5.2 LOG-RANK TESTS
If everyone randomized to the initial treatment Aj remained on B1 once they responded to
Aj (that is, were there no second randomization), we could have observed the event times
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Uj1i = min(Tj1i, Ci) for the treatment strategy AjB1, j = 1, 2. A two sample standard log-
rank statistic could then be used to test the null hypothesis of no difference between the
two survival distributions related to the strategies A1B1 and A2B1. Using counting process
representations [11], the standard log-rank test statistic could then be represented as
ZLRn (t) =
∫ t
0
Y11(s)Y21(s)
Y11(s) + Y21(s)
{
dN11(s)
Y11(s)
− dN21(s)
Y21(s)
}
, (5.1)
where Nj1i(s) = I(Uj1i ≤ s,∆i = 1), Yj1i(s) = I(Uj1i ≥ s), Nj1(s) =
∑n
i=1Nj1i(s) and
Yj1(s) =
∑n
i=1 Yj1i(s) for j = 1, 2. Under the null hypothesis of no difference between two
treatment strategies, n−1/2ZLRn (t) is asymptotically normally distributed with mean zero and
a variance that is consistently estimated by σ2n
LR
(t), where
σ2n
LR
(t) = n−1
∫ t
0
Y11(s)Y21(s)
Y11(s) + Y21(s)
{
dN11(s) + dN21(s)
Y11(s) + Y21(s)
}
.
For details on the properties of the log-rank statistic, we refer the readers to Fleming and
Harrington [11].
In a TSRD study, however, Uj1i could not be observed for patients who are assigned
to induction treatment Aj but randomized to maintenance treatment B2 after responding
to Aj. In order to account for the second randomization, Guo [12] modified the standard
log-rank test by assigning a time-dependent weight to each observation, and using inverse
weighting methods to derive a weighted log-rank test statistic. The weight function is defined
as Wi(s) = 1 − Ri(s) + Ri(s)Xi/piz, where Ri(s) = RiI(TRi ≤ s) and piz is the probability
of a patient being assigned to maintenance treatment B1 given that they responded and
consented. In other words, if a patient has not responded at time s, they will have weight
Wi(s) = 1; if the patient has responded/consented by time s and is assigned to B1 in the
second randomization, Wi(s) = 1/piz; however, if the patient has responded/consented by
time s and is assigned to B2, which is not consistent with treatment strategy AjB1, then
Wi(s) = 0. Define Nji(s) = I(Ui ≤ s,∆i = 1, Zi = 2− j), Yji(s) = I(Ui ≥ s, Zi = 2− j) and
let Y j(s) =
∑n
i=1Wi(s)Yji(s), N j(s) =
∑n
i=1Wi(s)Nji(s), be the weighted versions of at-risk
and the death processes for the jth induction treatment. Based on these weighted processes
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Guo [12] proposed the following inverse-probability-of-randomization-weighted (IPRW) log-
rank statistic
Zn(t) =
∫ t
0
Y 1(s)Y 2(s)
Y 1(s) + Y 2(s)
{
dN1(s)
Y 1(s)
− dN2(s)
Y 2(s)
}
. (5.2)
It has been shown that under the null hypothesis n−1/2Zn(t) is asymptotically normally
distributed with mean zero and variance
σ2(t) =
2∑
j=1
E

[∫
S
(c)
3−j(u)
S
(c)
1 (u) + S
(c)
2 (u)
n∑
i=1
Wi(u){dNji(u)− λ(u)Yji(u)du}
]2 , (5.3)
where S
(c)
j (u) = P (Uj1 ≥ u) is the distribution of the overall survival time for treatment
policy AjB1. Consequently, Guo [12] proposed to use the standardized IPRW log-rank
statistic Tn(L) = n
−1/2Zn(L)/σn(L) to test the equality of survival curves between strategies
A1B1 and A2B1, where σ
2
n(t) is a consistent estimator of σ
2(t).
Of importance to note here is that although the IPRW log-rank statistic accounts for
the randomization in the second stage, it does not assign variable weights, for example, to
early and late failures. To account for this, we define the following class of general IPRW
log-rank statistics
Zφn(t) =
∫ t
0
φˆn(s)
Y 1(s)Y 2(s)
Y 1(s) + Y 2(s)
(
dN1(s)
Y 1(s)
− dN2(s)
Y 2(s)
)
, (5.4)
where φˆn(s) is a weight function uniformly consistent for some limiting function φ(s) over
all closed subintervals of [0, L) [13].
We show in section 5.3 that the variance of n−1/2Zφn(t) can be consistently estimated by
σ2
φ
n (t) = n
−1
∫ t
0
{
φˆn(s)
}2 Y 22(s)∑ni=1W 2i (s)Y1i(s) + Y 21(s)∑ni=1W 2i (s)Y2i(s)
[Y 1(s) + Y 2(s)]2
{
dN1(s) + dN2(s)
Y 1(s) + Y 2(s)
}
.
(5.5)
Corresponding standardized log-rank test statistics would be given by Tn(L), where Tn(t) =
n−1/2Zφn(t)/σ
φ
n(L) and the supremum version by supt∈(0,L) |Tn(t)|. In the next section we will
describe the limiting distribution of this statistic based on which a sample size formula will
be derived.
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5.3 LARGE SAMPLE PROPERTIES OF SUPREMUM LOG-RANK TEST
Eng and Kosorok introduced a sample size formula for the supremum log-rank statistic
for two-sample censored data based on the standard contiguous time-varying proportional
hazard alternative [13, 19], namely, the hazards of the two comparison groups are λn1 (t) =
λ0(t)exp(φ(t)γ
∗/2n1/2) and λn2 (t) = λ0(t)exp(−φ(t)γ∗/2n1/2), where λ0(t) is a continuous
baseline hazard and γ∗ is a scalar constant. We will use the same alternative for hazards
λn1 (t) and λ
n
2 (t) for strategies A1B1 and A2B1 respectively.
Let Λnj (t) =
∫ t
0
λnj (s)ds, Λ
0(t) =
∫ t
0
λ0(s)ds, and
M j(t) = N j(t)−
∫ t
0
Y j(s)dΛ
n
j (s). (5.6)
Since Nji(t) jumps only when the i
th individual from the jth strategy fails, we can eas-
ily see that Wi(t)Nji(t) = Wi(t)∆iI(Ui ≤ t)I(Xi = 2 − j), leading to d(Wi(t)Nji(t)) =
Wi(Ui)∆iI(Ui = t)I(Xi = 2− j) =Wi(t)dNji(t). Thus we can write,
dM j(t) = dN j(t)− Y j(t)dΛnj (t)
= d
n∑
i=1
Wi(t)Nji(t)−
n∑
i=1
Wi(t)Yji(t)dΛ
n
j (t)
=
n∑
i=1
Wi(t)dMji(t), (5.7)
where Mji(t) = Nji(t) −
∫ t
0
Yji(s)dΛ
n
j (s) is a continuous-time martingale. Now n
−1/2Zφn(t)
can be written as
n−1/2Zφn(t) = Gn(t) +Rn(t), (5.8)
where,
Gn(t) = n
−1/2
∫ t
0
φˆn(s)
Y 1(s)Y 2(s)
Y 1(s) + Y 2(s)
{
dM1(s)
Y 1(s)
− dM2(s)
Y 2(s)
}
, (5.9)
and
Rn(t) = n
−1/2
∫ t
0
φˆn(s)
Y 1(s)Y 2(s)
Y 1(s) + Y 2(s)
(dΛn1 (s)− dΛn2 (s)). (5.10)
Now, Gn(t) can be expressed as
n−1/2
[
n∑
i=1
∫ t
0
φˆn(s)
Y 2(s)Wi(s)
Y 1(s) + Y 2(s)
dM1i(s)−
n∑
i=1
∫ t
0
φˆn(s)
Y 1(s)Wi(s)
Y 1(s) + Y 2(s)
dM2i(s)
]
. (5.11)
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By the martingale central limit theorem [11], Gn(t) converges to a mean zero Gaussian
process with variance equal to the limiting value of
n−1
2∑
j=1
n∑
i=1
∫ t
0
{
φˆn(s)
}2 Y 23−j(s)W 2i (s)
[Y 1(s) + Y 2(s)]2
Yji(s)dΛnj (s)
≈ n−1
∫ t
0
φ2(s)
dΛ0(s)
[Y 1(s) + Y 2(s)]2
{
Y
2
2(s)
n∑
i=1
W 2i (s)Y1i(s) + Y
2
1(s)
n∑
i=1
W 2i (s)Y2i(s)
}
.(5.12)
The variance formula (5.12) leads to the consistent variance estimator (5.5).
5.4 A SAMPLE SIZE FORMULA FOR COMPARING SURVIVAL CURVES
Let n be the total number of patients and n1 and n2 be the number of patients assigned to A1
and A2, respectively. Assume that nj/n converges to aj ∈ (0, 1), j = 1, 2. Define piNRj (s) to
be the limiting distribution of
∑n
i=1(1−Ri(s))Yji(s)/nj, i.e., the proportion of patients who
haven’t responded to Aj at time s and are still at risk at time s among those who received
Aj, and pi
R
j1(s) be the proportion of patients who have been assigned to AjB1 and are still
at risk at time s among those who received Aj. Under these assumptions, we can write
n∑
i=1
W 2i (s)Y1i(s) =
∑
(1−Ri(s))Y1i(s) + 1
pi2z
∑
Ri(s)ZiY1i(s)
≈ na1piNR1 (s) +
1
pi2z
na1pi
R
11(s), (5.13)
and similarly,
n∑
i=1
W 2i (s)Y2i(s) ≈ na2piNR2 (s) +
1
pi2z
na2pi
R
21(s), (5.14)
and
Y j(s) ≈ najpiNRj (s) +
1
piz
najpi
R
j1(s), j = 1, 2. (5.15)
If we assume that the censoring and response rates are similar in the two induction treatment
groups, then for example we can further write piNR1 (s) = pi
NR
2 (s) = pi
NR
0 (s) and pi
R
11(s) =
piR21(s) = pi
R
0 (s). Consequently, equation (5.12) can be uniformly consistently approximated
by ∫ t
0
a1a2φ
2(s)
(
piNR0 (s) +
piR0 (s)
pi2z
)
dΛ0(s) = a1a2Dφ(t) (5.16)
38
where
Dφ(t) =
∫ t
0
φ2(s)piNR0 (s)dΛ0(s) +
1
pi2z
∫ t
0
φ2(s)piR0 (s)dΛ0(s)
=
∫ t
0
φ2(s)dDNR(t) +
1
pi2z
∫ t
0
φ2(s)dDR(t), (5.17)
where DNR(t) is the probability of observing an event by time t from the patients who are
yet to respond by time t, DR(t) is the probability of observing an event by time t from the
patients who have responded and received maintenance treatment B1.
On the other hand, a Taylor series expansion of
√
n(dΛn1 (s)− dΛn2 (s)) shows that under
the hypothesized contiguous alternative Rn(t) can be written as
Rn(t) = n
−1
∫ t
0
φˆn(s)
Y 1(s)Y 2(s)
Y 1(s) + Y 2(s)
√
n(dΛn1 (s)− dΛn2 (s))
≈ n−1
∫ t
0
φ(s)
Y 1(s)Y 2(s)
Y 1(s) + Y 2(s)
γ∗φ(s)λ0(s)ds,
which converges uniformly in probability to∫ t
0
a1a2φ
2(s)
(
piNR0 (s) +
piR0 (s)
piz
)
γ∗dΛ0(s) = γ∗a1a2D′φ(t), (5.18)
where
D′φ(t) =
∫ t
0
φ2(s)dDNR(t) +
1
piz
∫ t
0
φ2(s)dDR(t) (5.19)
We can set γ∗ = n1/2γ (for the purpose of determining the sample size), where γ refers
to a fixed alternative, in which case n−1/2Zφn(t) converges weakly to the Gaussian process
W (a1a2D(t)) + n
1/2γa1a2D
′(t), where W (·) is a standard Brownian motion.
Using an entirely similar sets of arguments, it can be shown that σ2
φ
n (t) in Equation (5.5)
converges uniformly to a1a2Dφ(t). Thus if we define u(t) = Dφ(t)/Dφ(L) and assume that
κ = D′φ(t)/Dφ(t) is a constant over time, then Tn(t) converges weakly to
T (t) =
W (a1a2Dφ(t))√
a1a2Dφ(L)
+
γa1a2
√
nD′φ(t)√
a1a2Dφ(L)
∼ W
(
Dφ(t)
Dφ(L)
)
+ γκ
√
a1a2nDφ(L)
Dφ(t)
Dφ(L)
= W (u(t)) + µu(t), (5.20)
where µ = γκ
√
a1a2D and D = nDφ(L).
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By definition, the assumption that κ is a constant follows when DR(t) and DNR(t) are
proportional over time, i.e, the death rate for responders is proportional to that for the
non-responders. This assumption also holds approximately if DNR(t) is large compared to
DR(t), in which case (5.17) and (5.19) are dominated by the first term in their expressions.
We notice that the expression (5.20) is a Brownian motion process with drift µ, denoted by
Wµ(u). To compute the sample size required to achieve a power 1− β when the type I error
is α in a two-sided hypothesis testing, we set φ(t) = 1 (proportional hazard alternative). We
then follow the procedure outlined in Eng and Kosorok [13] to obtain the critical value S1−α
for the supremum of standard Brownian motion such that
P ( sup
u∈[0,1]
|W (u)| > S1−α) = α. (5.21)
We then solve for µ in the following expression
Φ(S1−α − µ) + e2µS1−αΦ(S1−α + µ) = 1− β, (5.22)
where Φ = 1−Φ and Φ is the standard normal cumulative distribution. Finally, we compute
D =
µ2
a1a2γ2κ2
, (5.23)
and n = D/D(L) is the required sample size. Routines for conducting the supremum/standard
weighted log-rank test using software package R [18] is in Appendix A.2, and for calculating
the sample size for supremum weighted log-rank test is in Appendix A.3. Notice that in
the case where piz = 1, that is, if there were no second randomization, then Dφ(t) = D
′
φ(t),
leading to κ = 1, and the sample size formula coincides with the Eng and Kosorok’s [13]
sample size formula for the two-sample supremum log-rank test.
In the standard inverse-probability-of-randomization-weighted log-rank test, since the
statistic Tn(L) is asymptotically normally distributed with mean µ = γκ
√
a1a2D, the corre-
sponding sample size can be calculated using Schoenfeld’s (1983) Formula, i.e.,
D =
(Z1−α/2 + Z1−β)2
a1a2γ2κ2
, n = D/D(L). (5.24)
where Zq is the qth quantile of the standard normal distribution. We will compare the sample
sizes resulting from the above two methods in our simulation study in section 5.6.
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5.5 ANALYSIS OF CALGB 8932 DATA
We apply the supremum weighted log-rank test to a dataset from the CALGB 8923 trial
reported by Stone et al. [3]. In the trial, 388 elderly patients with acute myelogenous
leukaemia were randomized to two initial treatments following chemotherapy, 193 patients
received infusions of granulocyte macrophage colony-stimulating factor, GM-CSF, and 195
patients received placebo. In the second stage, 37 out of the 79 patients who responded and
consented in the GM-CSF group and 45 out of the 90 patients who responded and consented
in the placebo group were randomized to intensification therapy I. The remaining patients
who responded and consented were assigned to intensification therapy II. The goal was to
compare survival distributions under different induction and maintenance combinations.
As a result of the thorough follow-up and the short survival times, 361 deaths were
observed during the study length of over 3000 days. Since the responders responded at
different times, each of them was assigned a set of time-varying weights depending on whether
or not they had responded at that time and the status of their second-stage randomization.
Figure 5.1 compares the survival curves estimated using Guo & Tsiatis’s weighted risk
set estimates for two pairs of treatment strategies: GM-CSF/Intensification I vs. Placebo/
Intensification I, and GM-CSF/Intensification II vs. Placebo /Intensification II. Based on
the standard weighted log-rank test, the first comparison yielded a p-value of 0.088 while the
supremum weighted log-rank test described in section 5.2 produced a p-value of 0.178. For
the second comparison the p-values were respectively 0.39 and 0.54 for weighted log-rank
test and the supremum weighted log-rank test. Based on the results of supremum log-
rank test, GM-CSF and Placebo had slightly different effects in treating acute myelogenous
leukaemia patients when followed by intensification therapy I, but that, if they were followed
by intensification therapy II, no significant difference was detected. The p-values from the
supremum weighted log-rank test were larger than that from the standard weighted log-rank
test. As shown in the hazard plots in Fig. 5.2, the hazard rates of the groups being compared
cross over during the course of study, which indicates violation of the proportional hazard
assumption. As a result, the supremum weighted log-rank test is more appropriate than the
standard weighted log-rank test for this dataset.
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Figure 5.1: Leukaemia dataset. (a) Weighted risk set estimates of survival probability
for strategies GM-CSF/Intensification I, solid line, and Placebo/Intensification I, dashed
line, (b) for strategies GM-CSF/Intensification II, solid line, and Placebo/Intensification II,
dashed line.
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Figure 5.2: Leukaemia dataset. (a) Nonparametric hazard function estimates for strategies
GM-CSF/Intensification I, solid line, and Placebo/Intensification I, dashed line, (b) for GM-
CSF/Intensification II, solid line, and Placebo/Intensification II, dashed line.
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Figure 5.3: Hazard (left) and survival (right) functions when the hazards ratio between
the two groups is 2. Dashed lines are for treatment strategy A2B1 and solid lines are for
treatment strategy A1B1.
5.6 SIMULATION STUDIES
A series of Monte Carlo simulations were conducted to evaluate the proposed sample size
formula for comparing treatment strategy A1B1 and A2B1. In the first simulation scenarios,
following Lokhnygina and Helterbrand [9], to ensure a proportional hazard relationship be-
tween those two groups, we define the survival distribution for each strategy as a mixture of
distributions for responders and nonresponders:
Sj(t) = θjSR,j(t) + (1− θj)SNR,j(t), j = 1, 2,
where
SR,j(t) =
{
1, t ≤ tresp,
θ−1j [exp{−λ0exp((j − 1)γ)(t)} − (1− θj)cjexp(−λNRj (t))], t > tresp
, (5.25)
SNR,j(t) =
{
(1− θj)−1[exp{−λ0exp((j − 1)γ)t} − θj], t ≤ tresp,
cjexp(−λNRj t), t > tresp,
(5.26)
44
tresp is the time of the response assessment, θj is the proportion of responders in the induction
treatment group Aj, e
γ is the hazard ratio for group A2B1 relative to A1B1, and cj is the
normalizing constant.
Since we are only interested in comparing A1B1 and A2B1 in this demonstration, the
survival distribution for responders assigned to B2 was simulated to be the same as those
assigned to B1. The baseline hazard λ0 was set to be 0.8. The proportion of responders in
treatment arms A1 and A2 are 0.5 and 0.4, respectively, and λ
NR
1 = 0.85, λ
NR
2 = 0.88, and
tresp = 0.35(years). All patients who were still at risk at time L = 2.0(years) are censored
at that time. Figure 5.3 illustrates the survival functions for the two comparison groups
when the hazard ratio is 2.0.
We considered two values of type I error, α = 0.01 and α = 0.05, two target powers, 0.80
and 0.90, and two values of the hazard ratio, 2.0 and 1.6. Also, censoring times were assumed
to be distributed uniformly on the interval (0, 3.0) or (0, 2.05), yielding respectively 30% and
40% of observations censored. For each of the above 24 scenarios, 5000 Monte Carlo datasets
were generated for the sample size calculated from the formula proposed for the supremum
weighted log-rank test in section 5.4. Then both standard and supremum log-rank tests were
performed on each dataset and observed powers were calculated as the proportion of times
on which the null hypothesis was rejected. To see how the false rejection rate of the test
matched up to the nominal value, we also generated data from the null hypothesis, γ = 0,
and obtained the rejection rates.
The results are shown in Table 5.1 for 30% censoring, when censoring time was distributed
as Un(0, 3.0) and 40% censoring, when censoring time was distributed as Un(0, 2.05). The
target powers were achieved in almost all scenarios, and the type I errors were close to the
nominal level. The power of the supremum weighted log-rank test were very close to that of
Guo’s standard test [12] in most scenarios, and the sample sizes required by the two tests
did not differ by more than 6%.
To assess the sensitivity of the sample size and power to the assumption of constant κ,
we considered other sets of simulations. Table 5.2 shows the results when κ was defined
by κ = D′(L/2)/D(L/2), instead of κ = D′(L)/D(L) in Table 5.1, in other words, it was
evaluated at the middle of the following-up time interval instead of at the last time point.
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Table 5.1: Sample size, achieved power and type I error when comparing the survival curves
under treatment strategies A1B1 and A2B1 using supremum IPRW log-rank test and stan-
dard IPRW log-rank test based on 5000 Monte Carlo data sets. The results from regular
IPRW log rank test are given in parentheses. κ in Equation (5.23) is taken as D′(L)/D(L).
The rejection rates for IPRW log-rank test are based on the sample size from the Supremum
IPRW log-rank test.
Hazard Target Target type I Sample
% Censored ratio(eγ) power error(α) size Observed power False rejection rate
30 % 2.0 0.80 0.05 136(128) 0.790(0.845) 0.051(0.062)
0.01 198(191) 0.815(0.826) 0.011(0.011)
0.90 0.05 181(172) 0.896(0.920) 0.047(0.056)
0.01 252(243) 0.911(0.920) 0.008(0.011)
1.6 0.80 0.05 306(289) 0.818(0.829) 0.053(0.062)
0.01 447(430) 0.825(0.849) 0.012(0.019)
0.90 0.05 408(387) 0.918(0.921) 0.056(0.062)
0.01 568(548) 0.913(0.925) 0.014(0.015)
40 % 2.0 0.80 0.05 153(145) 0.812(0.843) 0.048(0.067)
0.01 224(215) 0.829(0.848) 0.010(0.012)
0.90 0.05 204(194) 0.919(0.936) 0.048(0.061)
0.01 284(274) 0.921(0.930) 0.009(0.010)
1.6 0.80 0.05 344(326) 0.830(0.837) 0.056(0.062)
0.01 504(485) 0.829(0.861) 0.013(0.018)
0.90 0.05 460(436) 0.920(0.936) 0.054(0.060)
0.01 641(618) 0.913(0.924) 0.012(0.015)
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Table 5.2: Sample sizes, achieved powers and type I errors when comparing the sur-
vival curves under treatment strategies A1B1 and A2B1 using the supremum inverse-
probability-of-randomization-weighted log-rank test and the standard inverse-probability-
of-randomization-weighted log-rank test based on 5000 Monte Carlo datasets. The results
from the standard log-rank test are given in parentheses. The value of κ in equation (5.23)
is taken as κ = D‘(L/2)/D((L/2). The rejection rates for the standard log-rank test are
based on the sample size from the supremum test.
Hazard Target Target type I Sample
% Censored ratio power error size Observed power False rejection rate
30 % 2.0 0.80 0.05 126(119) 0.769(0.779) 0.041(0.052)
0.01 184(177) 0.764(0.811) 0.008(0.011)
0.90 0.05 168(160) 0.877(0.889) 0.043(0.055)
0.01 234(226) 0.880(0.896) 0.010(0.012)
1.6 0.80 0.05 282(267) 0.804(0.829) 0.054(0.057)
0.01 412(396) 0.811(0.823) 0.012(0.018)
0.90 0.05 376(357) 0.908(0.919) 0.052(0.060)
0.01 524(505) 0.904(0.913) 0.013(0.017)
40% 2.0 0.80 0.05 145(137) 0.801(0.833) 0.050(0.051)
0.01 212(204) 0.820(0.821) 0.009(0.012)
0.90 0.05 193(183) 0.908(0.922) 0.050(0.052)
0.01 269(259) 0.910(0.929) 0.012(0.012)
1.6 0.80 0.05 324(306) 0.795(0.821) 0.051(0.060)
0.01 474(456) 0.805(0.823) 0.011(0.014)
0.90 0.05 432(410) 0.916(0.919) 0.054(0.059)
0.01 602(581) 0.904(0.914) 0.013(0.016)
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Comparing to Table 5.1, both the sample size and observed power decreased, but the changes
were not substantial and the expected powers were still achieved: when the hazard ratio
was 1.6, the observed power was a little lower than expected, while, when it was 2.0, the
observed power was still higher than expected. Other choices of κ between D′(L/2)/D(L/2)
and D′(L)/D(L) resulted in sample sizes and powers comparable to those presented in Table
5.2. Thus the choice of κ had little impact on the sample size based on the supremum test.
Next we consider scenarios in which the hazard ratio between the two comparison groups
is not constant, i.e., when the proportional hazard assumption does not hold. In the scenarios
presented in Table 5.3, we generated data by setting the value of γ in equations (5.25) and
(5.26) to be log(1.86) over the time interval [0, 1.0], log(0.90) over the interval [1.0, 1.8] and
log(1.10) thereafter. Figure 5.4 shows the hazard and survival functions of the two groups
for the simulated data. It is clear that, although the hazards cross over at certain time
points, the survival curve for treatment strategy A2B1 is always below that for A1B1. The
goal is to see if the tests can still detect the difference in survival when the hazards are not
proportional. The sample sizes are computed based on supremum weighted log-rank test
with a proportional hazards assumption, where the log hazard ratio γ was set to log(1.6).
Table 5.3 shows that the powers observed for the supremum weighted log-rank test
achieved the desired levels in almost all scenarios, while the standard log-rank test, which
required proportional hazards assumption, failed to do so. The results provide strong evi-
dence that the supremum weighted log-rank test is more powerful than standard weighted
log-rank test in comparing strategies from TSRD when the alternative is not proportional
hazards.
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Figure 5.4: (a) Hazard and (b) survival functions when the hazards of the two groups are not
proportional. Dashed lines are for treatment strategy A2B1 and solid lines are for treatment
strategy A1B1.
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Table 5.3: Achieved powers when comparing the survival curves under treatment strategies
A1B1 and A2B1 using supremum inverse-probability-of-randomization-weighted log-rank test
and Guo’s inverse-probability-of-randomization-weighted log rank test, from simulation stud-
ies based on 5000 Monte Carlo datasets, when the alternative is non-proportional hazards.
Observed power
Target Target type I Sample Supremum Regular
% Censored power error(α) size IPRW LR test IPRW LR test
30 % 0.80 0.05 306 0.784 0.656
0.01 447 0.762 0.643
0.90 0.05 408 0.906 0.785
0.01 568 0.879 0.731
40 % 0.80 0.05 344 0.828 0.742
0.01 504 0.823 0.730
0.90 0.05 460 0.919 0.843
0.01 641 0.926 0.849
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6.0 DISCUSSION AND FUTURE WORK
Sequential randomization designs are being broadly accepted in clinical trials for the purpose
of conducting adaptive treatment strategies. While traditional methods of data analysis can
not make efficient use of all the information obtained from such trials, recent methodolo-
gies have shown considerable advancement in this area. Lunceford et al. [5] first proposed
methods for estimating survival distribution and mean restricted survival time for treatment
strategies from two-stage randomization designs. The inverse-probability-weighted estima-
tors proposed by them are consistent and asymptotically normal. However, these estimators
are not asymptotically efficient, mainly because they fail to take into account the information
from censored observations. Nevertheless, their method was the first valid approach toward
statistical inference from two-stage designs. The estimators developed by Wahed and Tsiatis
[6, 8] improves efficiency over Lunceford et al. [5] estimators by taking into account auxiliary
covariates, which provides additional gain in efficiency when the covariates are prognostic of
the survival time among responders. These estimators are not as simple or intuitive as the
inverse-probability-weighted estimator[5] or the weighted risk set estimator defined by Guo
and Tsiatis [10].
The weighted risk set estimator defined as a natural extension of the Aalen-Nelson es-
timator is more intuitive and easier to implement than other estimators such as inverse-
probability-weighted estimator or the regular asymptotically linear efficient estimator. Our
simulation study shows that weighted risk set estimator is the most efficient among the ones
discussed in chapter 3, however, the estimate of survival probability shows some bias in small
samples possibly due to its non-linear functional dependence on the cumulative hazard func-
tion. The small-sample bias of this estimator is larger than other estimates in most cases.
The regular asymptotically linear estimator proposed by Wahed and Tsiatis [8] is the most
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efficient in its class, i.e, the class of regular asymptotically linear estimators, although the
idea is not as intuitive and the implementation is more computationally involved.
For the purpose of comparing survival probabilities between different treatment strate-
gies, we presented a sample size formula based on an inverse-probability-weighted consistent
and asymptotically normal estimator. In determining the variance of the estimated differ-
ence between survival rates, we made the working assumption that the survival times follow
exponential distributions. The simulation results show that the sample size formula achieves
the desired power even when the true survival distributions are not exponential. This gives
our sample size formula a broader applicability. Possible future work includes the considera-
tion of informative censoring and the comparison among more than two strategies in similar
or more complex designs.
In comparing survival curves for different treatment strategies in two stage randomiza-
tion trials with censored data, we have presented a weighted supremum weighted log-rank
test. This approach takes into account the second randomization, which makes use of the
information for the non-responding patients as well as the patients assigned to other treat-
ment strategies, enhancing the efficiency of the test. The supremum weighted log-rank test
is more powerful than the usual log-rank test in the case of non-proportional hazard alterna-
tive. The sample size formula provided in our study is based on the limiting distribution of
the test statistic and the contiguous time-varying proportional hazard alternative, and has
been shown to provide desired power and nominal type I errors. As two-stage randomization
is being used in many clinical trials in recent times, there is a growing need for a sample size
formula for the purpose of designing such trials. The sample size formula developed in this
article will serve that need, while the supremum IPRW log rank test can serve as an efficient
tool to analyze such data.
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APPENDIX
PROGRAMS WRITTEN IN R c©
A.1 SAMPLE SIZE FOR INVERSE PROBABILITY WEIGHTED WALD’S
TEST FOR ADAPTIVE TREATMENT STRATEGIES
##########################################
# Name:
# Sample.Size.tsrd.walds
# Purpose:
# To calculate sample Size for comparing two two-stage adaptive treatment
# strategies sharing common induction treatment.
# Arguments:
# m0: mean survival time for the non-responders;
# m1: mean survival time for those who responded and received the
# maintenance treatment I;
# m2: mean survival time for those who responded and received the
# maintenance treatment II;
# pir: the response/consent rate;
# pi: the probability for a respondent to be randomized to the
# maintenance treatment I;
# t: the time at which survival probability to be compared;
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# LL: the restiction of lifetime (the uplimit of the survival time);
# c: the uplimit of the uniform distribution of censoring time,
# i.e, Censoring time ~ UNIF(0,c);
# alpha: pre-specified Type I error;
# beta: pre-specified Type II error.
##########################################
SampleSize<-function(m0,m1,m2,pir,pi,t,LL,c,alpha,beta)
{
alpha0<-1/m0;alpha1<-1/m1;alpha2<-1/m2;
S0.t<-exp(-t/alpha0);S11.t.star<-exp(-t/alpha1);S12.t.star<-exp(-t/alpha2);
F0.t<-1-S0.t;F11.t.star<-1-S11.t.star;F12.t.star<-1-S12.t.star;
F11.t<-(1-pir)*F0.t+pir*F11.t.star;S11.t<-1-F11.t;
F12.t<-(1-pir)*F0.t+pir*F12.t.star;S12.t<-1-F12.t;
cons<-1-pir+(pir/pi);
S0.u<-function(u){exp(-u/alpha0)};F0.u<-function(u){1-S0.u(u)};
S11.u.star<-function(u){exp(-u/alpha1)};
S12.u.star<-function(u){exp(-u/alpha2)};
F11.u.star<-function(u){1-S11.u.star(u)};
F12.u.star<-function(u){1-S12.u.star(u)};
F11.u<-function(u){(1-pir)*F0.u(u)+pir*F11.u.star(u)};
S11.u<-function(u){1-F11.u(u)}
F12.u<-function(u){(1-pir)*F0.u(u)+pir*F12.u.star(u)};
S12.u<-function(u){1-F12.u(u)}
Pr.T.u<-function(u){(1-pir)*S0.u(u)+pir*(pi*S11.u.star(u)
+(1-pi)*S12.u.star(u))};
Gprim.1<-function(u){-S11.t*F11.u(u)/Pr.T.u(u)};
Gprim.2<-function(u){-S12.t*F12.u(u)/Pr.T.u(u)};
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E.L2.1<-function(u){cons*(S11.u(u)-S11.t)-2*F11.t*cons*(S11.u(u)-S11.t)
+cons*(F11.t^2)*S11.u(u)+2*Gprim.1(u)*S11.t*F11.u(u)
+((Gprim.1(u))^2)*Pr.T.u(u)}; #E(L_11^2)
E.L2.2<-function(u){cons*(S12.u(u)-S12.t)-2*F12.t*cons*(S12.u(u)-S12.t)
+cons*(F12.t^2)*S12.u(u)+2*Gprim.2(u)*S12.t*F12.u(u)
+((Gprim.2(u))^2)*Pr.T.u(u)}; #E(L_12^2)
int.1<-function(u){E.L2.1(u)*(c)/((c-u)^2)};
int.2<-function(u){E.L2.2(u)*(c)/((c-u)^2)};
var.F11<-F11.t*S11.t*cons+integrate(int.1,0,LL)$value; # variance of phi_1
var.F12<-F12.t*S12.t*cons+integrate(int.2,0,LL)$value; # variance of phi_2
cov.fst<-pir*(1-pir)*F11.L.star*F12.L.star+(1-pir)^2*F0.L-(1-pir)*F11.L*F12.L
# first term in the covariance expression
E.L1L2<-function(u){
(1-pir)*((1-F11.t-F12.t)*(F0.t-F0.u(u))+F11.t*F12.t*(1-F0.u(u)))
+Gprim.2(u)*F11.u(u)*S11.t+Gprim.1(u)*F12.u(u)*S12.t
+Gprim.1(u)*Gprim.2(u)*Pr.T.u(u)
}; # E(L11*L12)
inter<-function(u){E.L1L2(u)*(c)/((c-u)^2)};
cov.snd<-integrate(inter,0,LL)$value;
# second term in the covariance expression
var.F11.F12<-var.F11+var.F12-2*(cov.fst+cov.snd) #variance of phi_1-phi_2
Delta=F11.u(t)-F12.u(t);
n<-((qnorm(1-alpha/2)+qnorm(1-beta))^2)*var.F11.F12/(Delta^2)
cat(’ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~’,’\n’,
’ H0: F11(’,t,’)= F12(’,t,’)=’,round(F11.t,2),’\n’,
’ Ha: F11(’,t,’)=’,round(F11.t,2),’ ,’, ’F12(’,t,’)=’,round(F12.t,2),’\n’,’
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Type I error: ’, alpha,’\n’,
’ Power : ’, 1-beta,’\n’,’ Requried Sample Size for the A1 arm:’,ceiling(n),’\n’,
’~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~’,’\n’ )
return(invisible(list("response rate"=pir,"randomization rate"=pi,
Delta=round(Delta,2),alpha=alpha,beta=beta,"sample size"=ceiling(n))))
}
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A.2 COMPARING ADAPTIVE TREATMENT STRATEGIES USING
SUPREMUM/STANDARD WEIGHTED LOG-RANK TEST
##########################################################################
# Name:
# sup.log.rank.two.stage
# Purpose:
# returns the p-value for the supremum weighted
# log-rank test proposed in chapter 5
# Arguments:
# time: the observed event time;
# delta: the censoring indicator, 1 if death, 0 if censoring;
# group: group indicator, 1 for A1, 2 for A2;
# R: response indicator, 1 for responders, 0 for non-responders;
# t.r: the time for assessing the response status;
# pi.z: the probability of responders to be randomized to second treatment B1;
# error: the tolerance.
# Acknowledgment:
# Functions associated with Brownian motion are in courtesy of Professor
# Kosorok of UNC Chapel Hill
##########################################################################
sup.log.rank.two.stage<-function (time, delta, group, R,Z,t.r, pi.z,error=1.0e-8)
{
sup.G<-function(x,m=10)
# This is to calculate the CDF of supremum Brownian motion
{
k<-m:0
(4/pi)*sum(((-1)^k)/(2*k+1)*exp(-(pi^2)*((2*k+1)^2)/(8*x^2)))
}
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cnorm<-function(z,thresh=3.6,delta=0.6,kk=4){
# This is to calculate the 1 - CDF of standard normal distribution
check<-F
if(z<0){
z<-(-1)*z
check<-T
}
if(z<thresh){
out<-1-pnorm(z)
}
else{
term<-1
tally<-term
if(kk>1){
for(k in 1:(kk-1)){
term<-(-1)*term*(2*k-1)/z^2
tally<-tally+term
}
}
out<-tally*dnorm(z)/z
if(z<thresh+delta){
x<-1-pnorm(z)
out<-x+(z-thresh)*(out-x)/delta
}
}
if(check){out<-1-out}
out
}
n<-length(time)
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weight<-rep(1,n)
X <- group - 1
n2 <- sum(X)
n1<- n-n2
Wb<-rep(1,n) # Weight Before time of response
Wa<-1-R+R*Z/pi.z # Weight After time of response
Iu1<-matrix(0,n1,n1);Iu2<-matrix(0,n2,n2)
y1.temp<-rep(0,n1);y2.temp<-rep(0,n2);d1.temp<-rep(0,n1);d2.temp<-rep(0,n2);
N.u1<-matrix(0,n1,n1);N.u2<-matrix(0,n2,n2);
y1.new.temp<-rep(0,n1);y2.new.temp<-rep(0,n2);
V1<-time[X==0]
V2<-time[X==1]
delta1<-delta[X==0]
delta2<-delta[X==1]
Wb1<-Wb[X==0];Wa1<-Wa[X==0]
Wb2<-Wb[X==1];Wa2<-Wa[X==1]
for (i in 1:n1)
{ Iu1[i,]<-ifelse(V1>=V1[i],1,0)
N.u1[i,]<-ifelse(V1<=V1[i],1,0)
y1.temp[i]<-sum((Wb1*(V1[i]<t.r[i])+Wa1*(V1[i]>=t.r[i]))*Iu1[i,])
y1.new.temp[i]<-sum((Wb1*(V1[i]<t.r[i])+Wa1*(V1[i]>=t.r[i]))^2*Iu1[i,])
d1.temp[i]<-(Wb1[i]*(V1[i]<t.r[i])+Wa1[i]*(V1[i]>=t.r[i]))*delta1[i]
}
for (i in 1:n2)
{ Iu2[i,]<-ifelse(V2>=V2[i],1,0)
N.u2[i,]<-ifelse(V2<=V2[i],1,0)
y2.temp[i]<-sum((Wb2*(V2[i]<t.r[i])+Wa2*(V2[i]>=t.r[i]))*Iu2[i,])
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y2.new.temp[i]<-sum((Wb2*(V2[i]<t.r[i])+Wa2*(V2[i]>=t.r[i]))^2*Iu2[i,])
d2.temp[i]<-(Wb2[i]*(V2[i]<t.r[i])+Wa2[i]*(V2[i]>=t.r[i]))*delta2[i]
}
new.v<-append(V1,V2)
mis<-rep(-1,n2)
y1.temp<-append(y1.temp,mis)
y1.new.temp<-append(y1.new.temp,mis)
mis<-rep(-1,n1)
y2.temp<-append(mis,y2.temp)
y2.new.temp<-append(mis,y2.new.temp)
mis.d<-rep(-1,n2)
d1.temp<-append(d1.temp,mis.d)
mis.d<-rep(-1,n1)
d2.temp<-append(mis.d,d2.temp)
otime<-order(new.v)
new.v<-new.v[otime]
y1<-y1.temp[otime];y1.new<-y1.new.temp[otime];
y2<-y2.temp[otime];y2.new<-y2.new.temp[otime];
d1<-d1.temp[otime];
d2<-d2.temp[otime];
for (i in (n-1):1){
if (y1[i]<0) y1[i]<-y1[i+1]
if (y2[i]<0) y2[i]<-y2[i+1]
if (y1.new[i]<0) y1.new[i]<-y1.new[i+1]
if (y2.new[i]<0) y2.new[i]<-y2.new[i+1]
}
y1.new.temptemp<-y1.new[y1.new>0]
y2.new.temptemp<-y2.new[y2.new>0]
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for (i in 1:n){
if (y1.new[i]<=0) y1.new[i]<-y1.new[length(y1.new.temptemp)]
if (y2.new[i]<=0) y2.new[i]<-y2.new[length(y2.new.temptemp)]
}
y1.temptemp<-y1[y1>0]
y2.temptemp<-y2[y2>0]
for (i in 1:n){
if (y1[i]<=0) y1[i]<-y1[length(y1.temptemp)]
if (y2[i]<=0) y2[i]<-y2[length(y2.temptemp)]
}
for (i in 1:n) {
if (d1[i]<0) d1[i]<-0
if (d2[i]<0) d2[i]<-0
}
#weight<-tapply(weight,time,"max")
w <- (y1 * y2)/(y1 + y2)
w.new<-(y1^2*y2.new+y2^2*y1.new)/(y1+y2)^2
terms <- (d1/y1 - d2/y2)[w > 0]
terms<-terms[!is.na(terms)]
temp<-y1+y2-1
temp<-ifelse(temp<1,1,temp)
cc<-1-(d1+d2-1)/temp
cc<-1
vterms <- (cc*(d1 + d2)/(y1 + y2))[w > 0]
weight<-weight[w > 0]
w <- w[w > 0]
w.new<-w.new[w.new>0]
#terms <- ( w * terms)/sqrt(sum( w * vterms))
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terms.new <- ( w * terms)/sqrt(sum( w.new * vterms))
temp<-c(0,cumsum(terms))
temp.new<-c(0,cumsum(terms.new))
xs<-max(temp.new)
xi<-min(temp.new)
if(abs(xs)>abs(xi)){test<-xs} else test<-xi
x <- abs(test)
m<-ceiling(max(c(1,(x*sqrt(2)/pi)*sqrt(max(c(1,log(1/(pi*error)))))-0.5)))
p<-1-sup.G(x,m=m)
out <- NULL
out$test <- test
out$p <- p
x.logrank<-temp.new[length(temp.new)]
out$test.logrank<-x.logrank
out$p.logrank<-2*cnorm(abs(x.logrank))
cat(’ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~’,’\n’,
’ Test statistics for Supremum weighted log rank test :’,test,’;’,’\n’,
’ P-value for Supremum weighted log rank test :’,p,’;’,’\n’,
’ Test statistics for Regular weighted log rank test :’,x.logrank,’;’,’\n’,
’ P-value for Regular weighted log rank test :’,out$p.logrank,’;’,’\n’,
’~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~’,’\n’ )
}
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A.3 SAMPLE SIZE FOR COMPARING ADAPTIVE TREATMENT
STRATEGIES USING SUPREMUM WEIGHTED LOG-RANK TEST
##########################################################################
# Name:
# sample.size.sup.log.rank.two.stage
# Purpose:
# Returns required sample size for comparing
# the two strategies A1B1 vs. A2B1;
# Arguments:
# alpha: Type I error rate ;
# power: desired power ;
# pi.z: proportion of responders to be randomized to second treatment B1;
# gamma: the hazard ratio of A1B1 vs A2B1 in the alternative hypothesis;
# D.NR.tau: expected proportion of death among the non-responders at the
# end of the study;
# D.R.tau: expected proportion of death among the responders at the end
# of the study;
# Acknowledgment:
# Functions associated with Brownian motion are in courtesy of Professor
# Kosorok of UNC Chapel Hill
##########################################################################
sample.size.sup.log.rank.two.stage<-
function(alpha,power,pi.z,gamma,D.NR.tau,D.R.tau)
{
sup.G<-function(x,m=10)
## This is to calculate the CDF of supremum brownian motion
{
k<-m:0
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(4/pi)*sum(((-1)^k)/(2*k+1)*exp(-(pi^2)*((2*k+1)^2)/(8*x^2)))
}
sup.g<-function(x,m=10)
## This is to calculate the PDF of supremum brownian motion
{
k<-m:0
(pi/x^3)*sum(((-1)^k)*(2*k+1)*exp(-(pi^2)*((2*k+1)^2)/(8*x^2)))
}
cnorm<-function(z,thresh=3.6,delta=0.6,kk=4){
## This is to calculate the 1-CDF of standard normal distribution
check<-F
if(z<0){
z<-(-1)*z
check<-T
}
if(z<thresh){
out<-1-pnorm(z)
}
else{
term<-1
tally<-term
if(kk>1){
for(k in 1:(kk-1)){
term<-(-1)*term*(2*k-1)/z^2
tally<-tally+term
}
}
out<-tally*dnorm(z)/z
if(z<thresh+delta){
x<-1-pnorm(z)
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out<-x+(z-thresh)*(out-x)/delta
}
}
if(check){out<-1-out}
out
}
sup.inverse<-function(alpha,error=1e-8)
# This is to calculate the critical value of
#supremum brownian motion: S_{1-alpha}
{
x<-qnorm(1-alpha/4)
temp<-max(1,2/x)
m<-ceiling((x/pi)*sqrt(2*log(temp/(pi*error)))-0.5)
if(m<0){m<-0}
interror<-1
while(interror>error)
{
yx<-sup.G(x,m=m)
dg<-sup.g(x,m=m)
delta<-(1-alpha-yx)/dg
x<-x+delta
interror<-sup.G(x)-(1-alpha)
}
x
}
sup.mu<-function(alpha, beta, error=1e-8)
# This is to calculate R (
#the ratio of sample size between supremum and regular)
{
u<-sup.inverse(alpha,error=error)
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y<-1-beta
ml<-qnorm(1-alpha/2)+qnorm(1-beta)
x<-ml
delta<-1
while(delta>error)
{
yx<-cnorm(u-x)+exp(2*x*u)*cnorm(u+x)
dp<-dnorm(u-x)-exp(2*u*x)*dnorm(u+x)+2*u*exp(2*u*x)*cnorm(u+x)
delta<-(y-yx)/dp
x<-x+delta
}
x
}
D.tau<-D.NR.tau+(1/pi.z^2)*D.R.tau
D.tau.prime<-D.NR.tau+(1/pi.z)*D.R.tau
kappa<-D.tau.prime/D.tau
mu.star<-sup.mu(alpha,1-power)
beta<-log(gamma)
D<-mu.star^2/(pi.z*(1-pi.z)*(beta)^2*kappa^2)
# size is the sample size using the supremum weighted log rank test #
size<-D/D.tau
size #146 when alhpa=0.05,beta=0.2, 195 when alhpa=0.05,beta=0.1
# size.wlr is the sample size using the regular weighted log rank test #
size.wlr<-(qnorm(1-alpha/2)
+qnorm(power))^2*D.tau/(pi.z*(1-pi.z)*(beta)^2*D.tau.prime^2)
size.wlr
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cat(’ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~’,’\n’,
’ Type I error :’,alpha,’;’,’Power :’,power,’;’,’\n’,
’ Probability of being randomized to B1 :’,pi.z,’;’,’\n’,
’ Hazard ratio : ’, gamma,’;’,’\n’,
’ Requried Sample Size Using Regular Weighted Log Rank Test:’,
ceiling(size.wlr),’\n’,
’ Requried Sample Size Using Supremum Weighted Log Rank Test:’,
ceiling(size),’\n’,
’~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~’,’\n’ )
return(invisible(list("randomization rate"=pi.z,alpha=alpha,power=power,
"hazard ratio"=gamma,"sample size.supremum"=ceiling(size),
"sample size.regular"=ceiling(size.wlr))))
}
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